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Abstract

CHARACTERIZATION OF STAPHYLOCOCCAL NUCLEASE AND TUDOR
DOMAIN CONTAINING PROTEIN 1 (SND1) AS A MOLECULAR TARGET IN
HEPATOCELLULAR CARCINOMA AND NON-ALCOHOLIC STEATOHEPATITIS

Nidhi Jariwala, PhD

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy in Integrative Life Sciences

Virginia Commonwealth University, 2017

Devanand Sarkar, M.B.B.S., PhD.
Associate Professor, Department of Human and Molecular Genetics
Virginia Commonwealth University
Richmond, Virginia

SND1, a subunit of the miRNA regulatory complex RISC, has been implicated as an oncogene in
hepatocellular carcinoma (HCC). Oncoprotein SND1 regulates gene expression at a posttranscriptional level in multiple cancers including hepatocellular carcinoma (HCC). In the
present study, we characterize oncogenic functions of SND1 in HCC employing a novel
transgenic mouse model (Alb/SND1) and present SND1 as a potential molecular target in HCC
management. We show that Alb/SND1 mice develop spontaneous HCC with partial penetrance
and exhibit more highly aggressive HCC induced by chemical carcinogenesis. Livers from
Alb/SND1 mice exhibit a relative increase in inflammatory markers and spheroid-generating
tumor initiating cells (TiC). Mechanistic investigations defined roles for Akt and NF-κB
signaling pathways in promoting TiC formation in Alb/SND1 mice. Intravenous administration
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of the selective SND1 inhibitor 3', 5'-deoxythymidine bisphosphate (pdTp) inhibited tumor
formation without effects on body weight or liver function. We conclude that SND1 drives prooncogenic transcriptomic and proteomic changes in hepatocyte resulting in aggressive HCC.
SND1 specific RNA interactome is identified with RNA immunoprecipitation sequencing
(RIPSeq) approach. With an adjusted p value of <0.01 and >2-fold enrichment over control, 282
mRNAs were identified to significantly associate with SND1 protein. We focused on the tumor
suppressor Protein Tyrosine Phosphatase non-receptor type 23 (PTPN23) because its regulation
by SND1 and its role in HCC are not known. In current study, we confirm that SND1 posttranscriptionally downregulates PTPN23. Pursuing functional studies with tetracycline inducible
overexpression system, we validate that PTPN23 inhibits tyrosine kinase signaling, proliferation,
epithelial to mesenchymal transition, migration, invasion and in vivo tumorigenesis.
Alb/SND1 mice also manifest steatosis and fibrosis at one year of age. Coupled with a proinflammatory hepatic phenotype, we conclude that Alb/SND1 livers present NASH. High fat diet
causes severe NASH and aggressive NASH induced HCC in Alb/SND1 mice. Serum and hepatic
lipid profiling shows that hepatocyte specific SND1 overexpression associate with elevated
triglyceride and cholesterol LDL levels. Contrarily, hepatocyte specific deletion of SND1
(SND1ΔHEP) in vivo, significantly protects against age dependent steatosis. Association of SND1
in NASH pathology is novel discovery and we present preliminary evidence confirming role of
SND1

in

promoting

NASH.

Role of staphylococcal nuclease and tudor domain containing 1 (SND1) in oncogenesis
Introduction
Cancer is a highly aggressive disease characterized by interplay of mutations that cause
cellular transformation and abnormal cell growth. Over the years, state-of-the-art studies have
provided significant insights into the pathogenesis of this highly complex disease. Cancer is now
well-defined by six hallmarks: sustained proliferative signaling, evasion of growth suppression,
invasion and metastasis, replicative immortality, angiogenesis and resistance to apoptosis (1).
Changes in expression patterns of any gene controlling these pathways initiate tumorigenesis that
has the potential of developing malignancy. With increasing number of mutations being
identified each day, that play a role in cancer development, molecular understanding of this
disease gets more complicated. Further adding to the complexity is the effect of environmental
factors in disease pathogenesis at each stage. Hanahan and Weinberg revised their benchmark
“Hallmarks in Cancer” to include two emerging hallmarks of tumorigenesis – reprogramming
energy metabolism and evading immune destruction (1). While the metabolic reprogramming of
cancer cells, also decribed at Warburg Effect is required to sustain incessant replicative potential,
evasion of immune recognition protects cancer cells from innate/ adaptive immune attack. Along
with aforementioned hallmarks of cancer, they describe two critical features that promote
tumorigenesis within an organ – tumor promoting inflammation and genomic instability (1).
Mutations arising in cells are mainly governed by genetic predisposition to changes in DNA
structure, stability and expression, epigenetic changes and environmental factors (2). Epigenetic
variations broadly include methylation pattern, microRNA expression disorders and chromatin
organization (2). Diversity in cancer is not just restricted to the factors leading to cancer
development, but is also affected by the tumor microenvironment, broadly classified as inter1

tumor heterogeneity and intra-tumor heterogeneity (2). With the advent of new technologies, the
molecular changes, which are responsible for such alterations, are being identified and a subset
of these can serve as potential therapeutic targets.
Role of immune system is intriguing in cancer. While immune evasion protects cancer
cells from immune system mediated cytotoxicity, several immune cell subtypes contribute
towards pro-tumorigenic microenvironment via cytokine secretome (1). Increased blood supply
and invasion of a tissue with immune cells such as macrophages, NK cells and cytotoxic T cells
upon cellular injury is traditionally described as inflammation. Immune cells are then responsible
for recognition and elimination of injured/ infected cells, resulting in necrosis and scarring of
tissue. Under healthy conditions, inflammation is tightly regulated by a complex network of
molecular signaling, required to prevent infections and heal tissue injury. Cancerous lesion is
infiltrated by varying proportion of immune cells, each contributing towards cytokine secretome
that promotes and maintains inflammation within the tumor and surrounding non-neoplastic
tissue. Independent molecular investigations have deduced specific signaling cascades resulting
from pre-existing inflammation that promote tumor development and growth. Cytokine network
sustains growth factor signaling, promotes angiogenesis and EMT, which are crucial hallmarks
of cancer (1). Interestingly, despite evident population of immune cells within tumor
microenvironment, cancer cells develop mechanisms to evade immune recognition by innate
response cells such as NK cells or dendritic cells and adaptive response cells such as cytotoxic T
cells. Selective inhibition of cell surface expression of antigenic peptides is one of the chief and
well-studied mechanism of cancer cells in evading tumor recognition.
Inflammation is an important hallmark of hepatocellular carcinoma (HCC) pathology.
HCC is a primary liver malignancy arising within hepatocytes, constituting >90% of liver
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malignancies and ranked second for global cancer related mortality (3). Within human patient
population, HCC is always diagnosed secondary to a pre-existing primary pathology that
promotes chronic inflammation (3). Pre-existing pro-inflammatory conditions create conducive
microenvironment for neoplastic transformation of hepatocytes. Hepatocyte injury due to
environmental stress initiates a complex signaling network that promotes hepatic stellate cell and
macrophage activation. Activated stellate cells and macrophages secrete pro-inflammatory
cytokines such as IL1β, TNFα and IL6 that regulate downstream inflammatory and prooncogenic signaling. Thus, inflammation of hepatic tissue eventually progresses into necrosis,
fibrosis, cirrhosis and carcinogenesis. Inherent genomic instability promotes pro-oncogenic
events, which allow progression from cirrhosis to HCC. NF-κB mediated inflammation is a
common pathological hallmark of HCC, across different primary pathology background. Some
of the other major signaling pathways promoting HCC are listed in Llovet et. al. (3). PI3K/AKT,
c-Met and EGFR signaling pathways have been demonstrated to promote HCC growth, and
inhibiting these pathways have shown significant success in pre-clinical models (3). This article
describes significance of each pathway to disease pathology and their relevance to molecular
targeting in HCC patients (3). However, small molecule inhibitors targeting key pro-oncogenic
signaling pathways in HCC have shown modest success at clinical trials. Sorafenib mediated
targeting of VEGF and RAF/MEK/ERK increases overall survival of patients by 2.8 months (4).
Regorafenib further enhances this overall survival period by additional 2.8 months. Efforts need
to be focused on not only enhancing overall survival period but allow disease free survival of
HCC patients. Oncoprotein discussed henceforth in this chapter is a functional link between
inflammation, pro-oncogenic growth receptor signaling and HCC, as illustrated by experimental
data in subsequent chapters.
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Staphylococcal nuclease and tudor domain containing 1 (SND1) is involved in
transcriptional activation, RNA splicing, editing and stability, and RNAi function (5-12). These
processes are relevant for regulation of gene expression. SND1 is predicted to manifest a
dynamic role modulating multiple molecular networks that control gene expression. Structural
analysis has confirmed that SND1 protein functions include nucleic acid interaction along with
protein-protein interactions (13). Several studies have illustrated the significant association of
SND1 with different types of cancers, including liver, breast, prostate and colorectal cancers and
malignant glioma (14-22). It is overexpressed in these cancers and known to promote
manifestation of aforementioned hallmarks of carcinogenesis. The present review provides a
comprehensive description of the functional aspects of SND1 that are relevant to cancer
development and progression.
SND1 protein structure
The human SND1 gene was assigned to chromosome 7q31.3 band location employing
restriction fragment and fluorescence in-situ hybridization (FISH) analyses (23). Genomic gain
in 7q, especially 7q31, has been demonstrated in prostate, renal and colorectal carcinoma (2426). SND1 is overexpressed in prostate and colorectal carcinoma (20,21) and genomic
amplification might be an underlying mechanism for this overexpression.
Human SND1 is a 910 a.a. containing protein with highly conserved domains found even
in Caenorhabditis elegans. SND1 comprises tandem repeats of four nuclease (SN) domains and
a fifth domain containing fusion of Tudor and partial nuclease domains (TSN) (13) (Figure 1).
The nuclease domains share 20% - 30% sequence homology (5). These domains have been well
characterized and found to be structurally related to staphylococcal nuclease (SN) domains (5).
These are thermonucleases that hydrolyze DNA and RNA in a calcium dependent manner (5).
4

However, hydrophobic cluster analysis shows that the SN domains of SND1 lack the specific
amino acid residues involved in calcium dependent catalytic activity (5). SN domains are
included in the oligonucleotide/oligosaccharide binding (OB) fold superfamily, which comprises
a large number of proteins, involved in nucleic acid binding (5). OB fold proteins are critical for
DNA replication, DNA recombination, DNA repair, telomeric maintenance and cold shock
response (27). OB fold domains range from 70-150 a.a. in length and consist of variable loops
between conserved secondary domains (27). Other than Staphylococcal Nucleases, OB fold is
also observed in bacterial enterotoxins, nucleic acid binding proteins and inorganic
pyrophosphates (27). Many of the proteins in OB fold family, lack catalytic activity but carry out
several other functions, such as transcriptional activation or repression, chromatin modification
and DNA repair (5,27). Tudor domains are highly conserved domains across eukaryotic species
and studied in great detail employing Drosophila as a model system (28). Tudor domain
containing proteins are involved in DNA interactions, specifically in epigenetic regulation, gene
expression as well as snRNP, miRNA and siRNA biogenesis (28). The presence of these
versatile SN and Tudor domains confer SND1 with its diverse multifunctional properties (Figure
1A).
Regulation of SND1 expression
The isolated 5’- flanking region of human SND1 gene spans more than 3.8 kb, including
transcription start site and translation initiation codon (29). Bioinformatics analysis revealed
presence of putative binding motifs for NF-κB, Sp1 and NF-Y transcription factors (29). The
core promoter region does not contain TATA box, but is rich in CpG islands to form preinitiation transcription complexes. The lack of a TATA box, an initiator sequence for
transcription, is complimented by the presence of a CCAAT box in the reverse orientation, i.e.,
5

ATTGG at position -61 and -28 (29). The CCAAT box and a GC box, at -48, act as positive
regulatory elements for SND1 expression (29). Inverted CCAAT sequences are often binding
targets for the NF-Y transcription factor. Luciferase assays with promoter deletion mutants show
that -274 to -112, containing potential binding sites for NF-κB and Sp1, are crucial for SND1
expression (29). Interaction of NF-κB, Sp1 and NF-Y with the SND1 promoter was also detected
by chromatin immnunoprecipitation (29). Mutation in GC box or CCAAT box reduced SND1
expression by 55-75%. As expected, TNF, an activator of NF-κB, induced SND1 transcription,
thereby suggesting the functional role of NF-κB in SND1 transcription regulation (29).
Promoter regions of the human, mouse and rat SND1 gene show about 80-85% sequence
homology (29). Similar findings have been observed in promoter analysis of rat homologue of
SND1, p102 (30,31). Putative binding sites for CCAAT/enhancer binding protein (C/EBP),
STATs and upstream stimulatory factor (USF) have been identified (30). NF-Y binds at the
CCAAT box (-370, -366), whereas the GC rich regions were identified as putative Sp1 binding
sites (31). DNA elements that matched the consensus binding sequences for liver specific
transcription factors, such as HNF-4, were also identified (30), suggesting that SND1 might be
differentially expressed in a tissue specific manner.
Fashe et al. investigated cellular localization and tissue specific expression of SND1 in
mice. With an exception of muscle tissues, SND1 is ubiquitously expressed in mice and the
expression patterns are mostly consistent to that reported in humans (32). SND1 is noticeably
upregulated in active secretory organs including pancreas, liver and mammary glands (32).
Studies have reported upregulated levels of SND1 in lipid droplets of milk secreting mammary
epithelial cells (33). SND1 levels were higher in exocrine pancreatic cells as compared to
endocrine cells (32). SND1 expression is lower in hepatocytes, however, it is overexpressed in
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sinusoid endothelial cells (32). Actively proliferating cells such as crypts of Lieberkuhn and
basal keratinocytes of skin and hair follicles show high SND1 protein levels compared to more
differentiated or terminally differentiated cells in the same tissue. SND1 protein levels are much
higher in spermatogonial cells than in spermatocytes and Sertoli cells. No protein is detected in
terminally differentiated spermatids and mature spermatozoa. In ovary, SND1 levels are high in
follicular cells compared to that in stromal cells. There is no SND1 protein in oocytes. SND1
protein levels are moderately expressed in human brain tissue, in neuronal as well as glial cells.
In mice kidney, SND1 is comparatively overexpressed in endothelial cells of Bowman’s capsule
than podocytes and mesangial cells. This protein is also expressed in bronchiolar epithelium,
alveolar cells and pneumocytes of lung. Within gastrointestinal system, SND1 is expressed in
ileum, deuodenum and colon. Lower SND1 levels are observed in more differentiated cells like
villi and Paneth cells in the ileum and absorptive cells of the colon. Overall, SND1 is
overexpressed in rapidly proliferating or precursor cells and downregulated in terminally
differentiated cells (32). SND1 is upregulated in T-cells and co-localizes with CD3, as observed
in lymphoid organs (32). Also, SND1 expression is not evident in macrophages, in lymphoid
organs as well as tissue residing macrophages like Kuppfer’s cells in liver and alveolar
macrophages in lungs. Further, SND1 levels in the red pulp of spleen are found to be higher than
that in white pulp. Differential expression of SND1 in T lymphocytes and macropahges suggests
a potential role of SND1 in regulating immunity.
Functions of SND1
Regulation of transcription
SND1, also called TudorSN or p100, was first identified as a transcriptional co-activator
in an attempt to identify proteins interacting with Epstein Barr Nuclear Antigen (34). EBNA2
7

specifically activates transcription of genes that mediate B lymphocyte transformation (34).
Along with known interacting factors such as TFIIB, TFIIH and TAF40, SND1 specifically
interacts with EBNA2 acidic domain (34). This interaction is mediated by SND1-TFIIE
interaction such that SND1 acts as an adapter protein between EBNA2 and the transcriptional
machinery (34). Pim kinase, found to be upregulated during Epstein Barr Virus infection, also
interacts with SND1 and mediate cellular transformation by cooperating to enhance c-Myb
activity (11). It was illustrated that Pim-1 phosphorylates SND1 and forms a stable complex,
leading to an induction in c-Myb activity (11). Ectopic expression of Ras and Pim-1 also induce
c-Myb responsive genes, since c-Myb is a downstream target in this signaling cascade (11). This
research study thus revealed that SND1 is a vital link in Ras- and Pim-1-mediated induction of cMyb (11). Lack of SND1 or dominant negative alleles of SND1 failed to cause an induction in cMyb activity (11). c-Myb is linked to proliferation and differentiation, and also known to
mediate cellular transformation. Hence, a role of SND1 in regulating c-Myb expression via Ras
or Pim-1 is significant in understanding its functional impact in oncogenesis.
Another important class of transcription factors that are known to interact and cooperate
with SND1 is Signal Transducers and Activator of Transcription, i.e., STATs (6,10,35). STAT
proteins are sequestered to Janus kinases (JAK), which upon stimulation by cytokines like IFN-γ,
undergo phosphorylation (36). Phosphorylation of STAT proteins and subsequent dimerization
leads to nuclear localization where it activates transcription of target genes (36). Constitutive
activation of the JAK-STAT pathway has been implicated in many cancers (36). There are seven
STAT proteins, which share structural and functional homology. Of these, SND1 is known to act
as a transcriptional co-activator for STAT5 and STAT6. SND1 co-immunoprecipitates with
STAT5, confirming the protein–protein interaction, but does not affect the phosphorylation
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status of STAT5 (10). Interaction with STAT5 is mediated via the SN domains as well as Tudor
domains of SND1, whereas STAT6-SND1 interactions involve only SN domains. SND1 acts as
an adapter molecule, allowing functional bridging between CREB binding proteins (CBP) and
STAT6 (35). It interacts with the D3-D4 domains of CBP and STAT6 transactivation domain
(TAD). Histone Acetylase Activity of CBP is stimulated by SND1, thereby allowing
transcriptional activation (35).
A recent study in a breast cancer model demonstrated that SND1 significantly interacts
with the promoter regions of several genes in the TGFβ signaling pathway, including Smad 1-4
and TGFβ (37). We have shown that SND1 up regulation also correlates with TGFβ signaling in
HCC, as described later in this review (18).
Post-transcriptional regulation of gene expression
Regulation of RNA-induced silencing complex (RISC) activity
Post-transcriptional regulation of gene expression can be mediated by several
mechanisms including nucleocytoplasmic localization, mRNA stability, mRNA processing and
translation. SND1 functions as a nuclease in RNA-induced silencing complex (RISC) that plays
a significant role in modulation of gene expression at a post-transcriptional level (8). Our studies
have shown that Astrocyte elevated gene-1 (AEG1), an important oncogene (38,39), in
association with SND1 and other proteins, forms a stable RISC complex (14). RISC incorporates
one strand of a small interfering RNA (siRNA) or microRNA (miRNA) and uses the siRNA or
miRNA as a template for recognizing complementary mRNA. Argonaute proteins are activated
in RISC when a complementary mRNA is identified which then cleaves the mRNA. SND1
functions as a nuclease in RISC along with the Argonaute proteins, while AEG-1 functions as a
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scaffold protein for proper assembly of this complex. Both SND1 and AEG-1 are overexpressed
in multiple cancers and together they facilitate functions of oncogenic miRNAs (onco-miRNA).
Indeed RISC activity in cancer cells was found to be higher than that in normal cells (14). The
increased activity of onco-miRNAs leads to increased suppression of their target tumor
suppressor genes. In HCC cells it was documented that overexpression of AEG-1 or SND1
resulted in decreased expression of several tumor suppressor genes that are targets of
oncomiRNAs, e.g., PTEN, target of miR-221 and miR-21; CDKN1C (p57), target of miR-221;
CDKN1A (p21), target of miR-106b; SPRY2, target of miR-21; and TGFBR2, target of miR-93
(14). The reverse finding was observed upon knockdown of SND1 or AEG-1 (14). These
findings suggest that increased RISC activity conferred by SND1 and AEG-1 might contribute to
the carcinogenic process (14).
In pancreatic cancer, synaptogamin-11 interacts with RISC via SND1 binding (40). It is
hypothesized that this protein is the missing link between membrane trafficking and miRNAmediated gene regulation (40). Synthesis of mature mir17-92 cluster is also inhibited by SND1
protein, thereby affecting several downstream target genes (41).
Regulation of mRNA stability
SND1 interaction with mRNA transcript can be independent of the RISC. Studies show
that SND1 interacts with 3’UTR of angiotensin II type 1 receptor (AT1R), a G protein coupled
receptor mediating the action of angiotensin (9). Here, SND1 increases mRNA stability and
translational efficiency by increasing AT1R mRNA half-life, resulting in elevated protein levels
(9). A recent finding shows that SND1 and AT1R mRNA colocalize in stress granules followed
by oxidative stress and SND1 is required for efficient protein–RNA aggregation (42). These
findings imply that SND1 increases stability of specific mRNAs, crucial for cellular stress
10

response (42). Using HCC cell lines, we have demonstrated that SND1-mediated increased
activity of AT1R activates the TGFβ signaling cascade thereby promoting epithelialmesenchymal transition (EMT) and an increase in migration and invasion (18). Studies have also
established interaction of SND1 and Dengue virus 3’UTR, leading to increased viral replication
(43). Further studies are required to determine whether SND1 plays a similar role in promoting
replication of Hepatitis B or C viruses (HBV or HCV), the most common cause of HCC.
Regulation of mRNA splicing
Splicing is an important post transcriptional event, involved in excluding the non-coding
intronic regions of mRNA transcript and thereby allowing translation of exonic regions into a
functional polypeptide (44). A large macromolecular complex, driven by several proteins is
required for this processing. Splicing is tightly regulated and functionally coupled with
transcription (44). Because differential regulation of genes influencing cell growth and
proliferation are critical for carcinogenesis, splicing is speculated to play a vital role in
establishing pathogenesis (45). The spliceosome complex is comprised of five major small
ribonucleoproteins – U1, U2, U4/U6 and U5 along with several small non-snRNP (44,46). SND1
interacts with the U5 component of the spliceosome and other non-snRNPs (46).
Immunoprecipitation studies with GST-TSN fusion protein (lacking SN domains) and GST-SN
fusion protein (lacking TSN domain) demonstrated that this interaction occurs specifically via
TSN domain (46). In vitro, exogenously added SND1 accelerated the kinetics of spliceosome
assembly, detected by a ligated mRNA product, in a dose-dependent manner (46). However, no
difference was observed in the amount of splicing products with or without SND1 (46). SND1
improved the efficiency of pre-spliceosomal Complex assembly and accelerated the formation of
complex B and complex C (46).
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Alternative splicing, observed in eukaryotes, allows translation of multiple polypeptides
from the same gene transcript by selection of specific exons to be included in the processed
mRNA (45). Recent reports indicate that deregulation of alternative splicing is associated with
cancer development and progression (45). SND1 plays a role in this biological process. SND1 is
identified as an interacting partner for SAM68, a pro-oncogenic RNA binding protein that is up
regulated in prostate cancer and supports cellular proliferation (47). SAM68 is involved in
alternative splicing of CD44, specifically favoring inclusion of exon v5 of this gene (47). Prior
studies indicate that inclusion of variable exons (v5) in CD44 mRNA correlates with cancer
development (47). SND1 functions as a positive regulator of the alternative splicing of CD44 via
SAM68. Knocking down SND1 inhibits inclusion of upstream variable exons (v4, v5 and v7),
whereas downstream variable exons (v8-v10) and constitutive exons are not affected (47). These
findings suggest that SND1 co-ordinates transcriptional and post-transcriptional events to
regulate gene expression. Future studies focused on splicing activity of SND1 might uncover
insights into the molecular events governing malignancy.
Regulation of RNA editing
Adenosine deaminase (ADAR) proteins function in RNA A-to-I editing by deaminating
Adenosine to Inosine, which is read as guanosine on an mRNA transcript (48). Such processes
regulate protein translation by functionally changing the mRNA sequence (48). This posttranscriptional regulation also plays a role in gene expression and miRNA processing (48).
Interestingly, ADAR protein expression is tightly regulated during embryogenesis, where it is
highest in the oocytes and zygote and diminished in the embryo stages (12). A strong correlation
was observed between ADAR and SND1 levels during mouse fertilization (12). While ADAR
marks hyper-edited transcripts, SND1 is responsible for degradation of hyper-edited mRNA
12

transcripts as well as miRNA precursors (12). The data suggests that SND1 and ADAR1 are
functionally synchronized in A-to-I editing and eliminate most miRNA precursors, progressively
from oocyte to zygote (12). However, this function is prohibited during embryogenesis. Thus,
SND1 plays a crucial role in early stage embryogenesis and cell differentiation (12). Analysis of
a SND1 knockout mouse will provide insights into the role of SND1 in regulating gene
expression during the developmental stage.
SND1 and stress response
SND1 plays a key role in cellular stress response via stress granule formation (49).
Several environmental stimuli can be stressful for cellular growth. In response to such stimuli,
cells undergo reprogramming in gene expression that allows cell survival (49,50). Initial studies
illustrated that SND1 is a component of the cytoplasmic stress granules and the SN domain is
crucial for this function (49,50). SND1 interacts with Ras GTPase Activating Protein SH3
Domain Binding Protein (G3BP) and Adenosine deaminase (ADAR1). While G3BP has been
shown to be essential for assembly of stress granules (49), ADAR1 has been linked to apoptosis
and stress response (50). ADAR1 levels are also induced by interferon and its deficiency causes
defective haematopoesis (50). Such studies implicate ADAR1 in cell survival and immune
response towards stress. SND1 was found to directly interact with ADAR1. These proteins colocalized within cytoplasmic stress granules following oxidative stress, heat shock or interferon
induction (50). Knockdown of SND1 prohibited assembly of smaller stress foci into larger
granules, emphasizing its role in this cellular function (49). These studies need to be extended in
vivo using appropriate experimental models to confirm the essential role of SND1 to cope with
stress responses.
Regulation of cell viability
13

SND1 is an essential protein in normal programmed cell death, a process mediated by
caspases (51). SND1 is cleaved by caspase 3 during drug-induced apoptosis. A non-cleavable
SND1 mutant increased cell viability and knocking down SND1 promoted drug-induced
apoptosis in HeLa cells (51). Incubation with caspases completely blocked RNase activity of
SND1 indicating that SND1 enzymatic activity is required for maintaining cell viability or
protection from apoptosis (51).
Oncogenic functions of SND1
Role of SND1 in Hepatocellular Carcinoma (HCC)
HCC is the primary liver malignancy, characterized as a highly aggressive form of cancer
(52). In most cases, HCC develops over a preexisting condition, such as liver cirrhosis,
nonalcoholic steatohepatitis and viral hepatitis infection (52). It is the fifth most common cancer
and ranks third in cancer-related deaths worldwide (52). Current management options include
surgical resection, and transarterial chemoembolization (TACE), though there is virtually no cure
for this cancer (53). Molecular approaches such as the multikinase inhibitor Sorafenib help to
moderately increase the survival of HCC patients (4). To curb the increasing mortality rate, there
is an urgent need for identification of potential therapeutic targets that can be employed for
translational applications.
Studies demonstrate multiple ways by which SND1 contributes to hepatocarcinogenesis.
Immunohistochemical analysis has demonstrated that SND1 is overexpressed in a high
percentage of HCC patients and SND1 levels correlate with HCC stage (14). Stable clones of
human HCC cells, with either overexpression or knockdown of SND1, in nude mice xenograft
studies confirmed the positive role of SND1 in regulating cell viability and growth (14). Since
SND1 is also an integral component of RISC complex, we investigated if RISC activity
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correlated with HCC development. Increased RISC activity was observed in HCC cell lines,
which consequently led to an increased downregulation of tumor suppressors via RNA
interference (14). As pointed out earlier, SND1 interacts and cooperates with AEG-1 to form
RISC along with other known RISC proteins and inhibition of SND1 activity diminished AEG-1
activity (14). Further investigation established that increased SND1 protein levels trigger a
cascade of molecular events that promote invasion, proliferation, migration and angiogenesis
(14,18,19). We unraveled a linear pathway in which NF-κB activation by SND1 augments miR221 levels (19). Target genes of miR-221, Angiogenin and CXCL16, were observed to promote
angiogenesis (19). Analysis of global gene expression profiles of SND1 knockdown HCC clones
identified 123 genes drastically down regulated, many of which are in the TGFβ signaling
pathway (18). We documented that increased stabilization of AT1R mRNA by SND1 activates
AT1R downstream signaling, such as activation of ERK1/2, culminating in activation of the
TGF signaling pathway. The TGF signaling pathway closely regulates EMT (18). Indeed, in
vitro analysis demonstrated increased invasion and migration in SND1-overexpressing clones
and vice versa in SND1 knockdown clones (18) and expression of EMT marker proteins, such as
N-cadherin, Slug and Snail and Vimentin, was found to be congruent with our hypothesis (18). A
tissue microarray on 50 HCC cases showed statistically significant correlation between AT1R
and SND1 levels further establishing a causative relationship between SND1, AT1R and TGF
in hepatocarcinogenesis (18).
IGF pathways are reported to be deregulated in HCC and found to be a cause of the
aggressive tumorigenesis. Insulin like growth Factor Binding protein 3, a negative regulator of
IGF pathway, was reported to be significantly over expressed in SND1 knockdown HCC clones
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(54). Thus SND1 might contribute to HCC by inhibiting IGFBP3 and promoting IGF-1 activity
(54).
SND1 promotes invasion and metastasis in breast cancer
Cancer cells possess the ability to invade circulatory system and establish tumors in
tissues distant from the primary site of tumorigenesis (55). Angiogenesis enables them to acquire
nourishment and growth factors for constitutive proliferation. Metastatic potential of a tumor is
often a measure of the fatality of the cancer. Metastasis has been long known to be a major cause
of disease relapse and cancer related deaths. More patients succumb to metastatic malignancy
than by the primary cancer. An efficient prognosis and diagnostic tool has not been discovered,
in spite of several attempts at analyzing differential expression patterns in tumorous tissue.
iTRAQ based proteomic analysis of a breast cancer metastasis model revealed that SND1
levels are up-regulated with carcinoma progression (15). This study aimed at studying gene
signatures in the breast cancer metastasis model. Out of the 197 proteins differentially regulated
in cancerous tissue as compared to normal tissue, only those that have not been reported in
association with metastasis were prioritized for further scrutiny (15). This approach helped
identify 10 novel proteins significantly associated with metastasis, employing Mass spectrometry
and immunohistochemistry. SND1 was one of these proteins, deregulated in breast cancer
metastasis and showed significant differential expression in normal versus breast cancer tissue
(15). Immunohistochemical analysis of a tissue microarray showed up-regulation of SND1 in the
majority of the cases (15).
AEG-1, also called Metadherin, is a known oncogene associated with most oncogenic
phenotype such as metastasis, invasion, angiogenesis, chemoresistance and apoptosis (56-60). A
study aimed at exploring role of AEG1 in breast cancer metastasis, identified SND1 as an AEG-1
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interacting protein (16). Role of SND1 in metastasis was further emphasized based on the global
gene expression profiling of SND1 knockdown clones. The list of gene sets globally enriched in
SND1-expressing control cells versus SND1-KD cells was strikingly dominated by those
involving genes up-regulated in some component of metastatic or oncogenic signaling (16).
Genes such as ANGPTL, ID1 and EREG, known to promote specifically lung metastasis in
breast cancer model, were significantly enriched in this gene set (16). An experimental lung
metastasis study in nude mice using a highly metastatic breast cancer cell line with SND1 knock
down showed dramatic reduction in pulmonary metastatic burden in vivo (16). Although SND1
did not promote invasion, it was found to augment chemoresistance to cells (16). SND1-KD cells
demonstrated sensitivity towards chemotherapeutic drug-induced apoptosis. Microarray data
from SND1-KD cells indicated up regulation of the KiSS1 gene (16). Reporter assays later
confirmed that SND1 directly down regulates the expression of the KiSS1 gene that is known to
suppress metastasis (61). Analysis of clinical data set of breast cancer patients with metastasis
revealed that SND1 levels strongly correlate with lung metastasis incidence and metastasis free
survival (16). Thus, SND1 is established to be a pro-metastasis protein. A recent finding shows
significant relationship between AEG-1-SND1 interactions and mammary tumorigenesis (17).
AEG-1 knockout cells show reduced tumor initiation and sphere formation in vivo (17). This
effect could be completely rescued by ectopic expression of AEG-1 in these cells (17). However,
knocking down SND1 in these cells completely abolished the rescue effect of ectopic AEG-1
(17). Knocking down SND1 in AEG1+/+ cells reduced the sphere formation in vitro and tumor
formation in vivo, resembling the phenotype of AEG1-/- cells (17). Thus, SND1 is essential for
pro-oncogenic properties of AEG-1 in breast cancer (17).
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Early studies have established that SND1 cooperates with c-Myb, a differentiation and
growth factor for immature hematopoetic stem cells promoting lymphocyte transformation (11).
Studies in breast cancer patients show overexpression of c-Myb as well as SND1 (62). A study
focused on identifying target genes of c-Myb revealed that the SND1 promoter is one of the
target sites of c-Myb (62). There might be a positive regulatory mechanism to maintain levels of
c-Myb and SND1 that potentially maintain tumorigenesis in breast cancer.
SND1: an efficient diagnostic marker for Prostate cancer and colorectal cancer
Studies focused on prostate cancer have identified SND1 as an efficient diagnostic
marker (20). In a study including 174 prostate cancer patients, SND1 levels correlated with
histological grade of the tumor (20). SND1 protein levels were comparable to alpha-methylacylcoA racemase (AMACR) protein levels, a currently employed marker protein for prostate cancer
diagnosis (20). Though there were some cases where SND1 and AMACR protein levels differed,
there was robust over expression of SND1 in tumorigenic tissue (20,47). It was suggested that
multiple protein markers, including SND1 and AMACR, should be used for better diagnosis of
the disease (20). Knocking down SND1 reduced proliferation of prostate cancer cells
demonstrating the importance of SND1 in maintaining prostate cancer viability (20). SND1 also
promotes prostate cancer development by positively regulating CD44 alternative splicing,
allowing inclusion of variable exon v5 that is known to be pro-oncogenic (47).
SND1 is significantly associated with colorectal cancer. A recent genome wide analysis
of methylation patterns in CRC patients revealed a pool of genes that are differentially
methylated in cancerous tissue in comparison to adjacent normal tissue (63). The study also
included tissue from normal, healthy patients with no familial history of CRC, as a control. A
CpG site located in SND1 gene was identified with highest discriminative accuracy, highlighting
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role of this protein in oncogenesis (63). Most of the hypermethylated CpG sites were within the
SND1 gene regions, whereas methylation in the promoter region of SND1 was observed to be
comparatively lower. Accordingly, SND1, along with other genes was identified as a potential
diagnostic candidate gene (63). Significant correlation was observed in nodal stage, pathological
stage and co-expression of SND1 and AEG-1 in colon cancer (64). Immunohistochemical
analyses of 196 colon cancer cases establish that cytoplasmic expression of AEG1 and SND1
protein positively correlates with tumor grade and cancer progression, but negatively correlates
with post-operative survival of patients (64). The study suggests potential application of these
proteins as prognostic markers for colon cancer (64).
SND1 downregulates Adenomateous Polyposis Coli protein levels by post-transcriptional
modification, without altering the mRNA levels of this gene, as reported in colon cancer (21).
APC is a tumor suppressor in colon carcinogenesis and also associated with maintaining cell
polarity and cell-cell adhesion by regulating E-cadherin localization (21). Loss of APC protein
leads to stabilization and subsequent accumulation of -catenin by preventing its proteasomal
degradation with subsequent loss of contact inhibition and increased proliferation (21). These
findings suggested that SND1 might be involved in early stage colon carcinogenesis. However,
whether miRNAs or RISC is involved in SND1-mediated downregulation of APC protein
remains to be studied.
SND1 in malignant glioma
Malignant gliomas are the most frequent malignant brain tumor in adults (65). Current
multi-modality therapies include surgery, radiation and chemotherapy, nonetheless the prognosis
of malignant glioma remains extremely poor (66). The rapid growth and highly invasive nature
of malignant glioma, favors its infiltration into surrounding normal brain parenchyma and
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facilitates recurrence after therapy (67). This aggressive disease progression necessitates further
understanding of molecular mechanism involved in glioma growth and invasion that ultimately
will lead to identification of novel therapeutic targets of translational relevance.
Our recent studies suggest that SND1 may provide a novel target for malignant glioma
treatment (22). In this study we found higher SND1 mRNA and protein in human malignant
glioma tissue as compared to normal brain. TCGA data showed a similar trend of high SND1
expression in human astrocytoma and glioblastoma samples as compared to normal brain.
Additionally Rembrandt data supports the prognostic significance of SND1 expression in which
patients with intermediate levels of SND1 survived longer than patients showing elevated SND1
expression. Overexpression (OE) and knock down (KD) studies were performed to unravel the
functional significance of SND1 in glioma progression. Overexpression of SND1 in
Immortalized primary human fetal astrocytes (IM-PHFA) (low SND1) significantly enhanced
invasion and colony formation as compared to parental IM-PHFA cells. Conversely when SND1
was knocked down in multiple glioma cell lines (high SND1) it significantly decreased invasion
and colony formation, both in monolayer and in soft agar. Interestingly SND1-KD primary
glioma cells demonstrated enhanced sensitivity towards Temozolomide, an FDA approved drug
used with radiation therapy as a standard of treatment for GBM patients (68). Knock down of
SND1 in malignant glioma cells resulted in a flat-shaped cells, which stained positive with galactosidase indicating induction of cellular senescence. Further studies documented a potential
involvement of STAT-3 in SND-1-mediating glioma invasion and senescence-induced cell
death. An intracranial xenograft study in nude mice using a highly invasive patient-derived
malignant glioma cell line, showed a significant improved survival in SND1–KD group. This
was associated with a significant decrease in proliferation marker, activated STAT3, and
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angiogenesis marker and an enhanced expression of apoptotic marker. The observation that
SND1 regulates several important determinants of glioma progression supports the rationale of
using SND1-inhibition as a means of treating glioma patients.
Specific inhibitors of SND1
BLAST search reveals that SND1 is the only eukaryotic protein with a Tudor and SN
fusion domain. Hence, this quaternary fold can be employed for targeted therapeutic approaches,
developing SND1 specific inhibitors. A similar protein domain is observed in Plasmodium
falciparum, a parasite causing malarial infections in humans. Studies with P. falciparum SND1
have confirmed that the SN domain is involved in nuclease activity, whereas the Tudor domain
carries out the function of RNA binding (69). 3′, 5′ -Deoxythymidine bisphosphate (pdTp) is a
competitive chemical inhibitor against SNases (8). In P. falciparum, it not only blocks the
nuclease activity, but also inhibits RNA/protein interaction of SND1 (69). pdTp inhibited growth
of both chloroquine-sensitive and chloroquine-resistant strains of P. falciparum at a
concentration of 100-200 M. Nevertheless, it did not inhibit the growth of human HCC cell line
Huh7-D12 at a concentration as high as 800μM suggesting that pdTp might be developed as an
anti-malarial drug (69). However, studies performed in our laboratory using multiple human
HCC cell lines demonstrated that pdTp treatment resulted in significant reduction in cell viability
and colony forming potential (14). However, this effect was observed at high concentrations,
ranging from 100-200 μM thus rendering it ineffective for clinical applications. Further high
throughput screening assays need to be performed to develop clinically relevant chemical
inhibitors against SND1 enzymatic activity. Employing the C terminus fusion domain of SND1
might prove to be a productive effort in designing targeted molecular therapy.
Conclusion and Future Direction
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SND1 is known to orchestrate a series of changes that affect global gene expression and
confer cellular transformation. It regulates gene expression employing multiple unique
mechanisms that function at transcriptional as well as post-transcriptional levels. With increasing
relevance of studies on SND1 in the context of carcinogenesis it is important to elucidate the
molecular mechanisms underlying SND1 activity. Studies so far suggest that it is a promising
molecule for clinical investigation and targeted therapeutic management of cancer. Considering
the pleiotrophic functions of SND1, one important question that has not been addressed is the
role of SND1 in maintaining normal physiological function(s) including growth and
development. An SND1 knockout mouse, conditional and global, will not only provide
comprehensive insights into the physiological functions of SND1, but also will be an ideal model
to interrogate the role of SND1 in immortalization, transformation, metastasis and overall cancer
development and progression. SND1 is not expressed in differentiated spermatocytes and
oocytes, indicating no role in fertilization. Since, SND1 regulates A-I transcript editing during
embryogenesis, it would be interesting to observe effect of SND1 knockout on embryonic
development and viability. Conversely, organ-specific SND1 transgenic mouse will also provide
useful insight into the oncogenic function of overexpressed SND1. Is SND1 overexpression
alone sufficient for transforming normal cells into cancer cells? Can SND1 function as a driver
for tumorigenesis or is it a passenger and expediter of transformation following initial mutagenic
events? Which particular aspects of SND1 function are most relevant to confer its oncogenic
properties? Future studies need to focus on and address these questions, which will provide
important insights into the precise role of SND1 in normal and abnormal physiology.
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Figure 1. SND1 protein structure and function. SND1 protein comprises of five domains
packed in helix-turn-helix model. Four domains are independent motifs of Staphylococcal
nuclease (SN) (A). SND1 is the only eukaryotic protein with a unique fusion domain – SN motif
fused with Tudor motif (A). SND1 regulates gene expression transcriptionally as well as posttranscriptionally to affect multiple hallmarks of cancer (B).
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Oncogenic Role of SND1 in Development and Progression of Hepatocellular Carcinoma
Introduction
Staphylococcal nuclease and tudor domain containing 1 (SND1) is a multifunctional
protein that regulates transcription, mRNA splicing, RNA editing, and miRNA-mediated mRNA
degradation as a nuclease in RNA-induced silencing complex (RISC) (6,8-10,12,13,46,70).
SND1 is overexpressed in multiple cancers, where it functions as an oncogene
(14,16,17,20,21,71). In hepatocellular carcinoma (HCC) SND1 overexpression was identified in
~74% cases (14). Overexpression of SND1 promotes and knockdown of SND1 inhibits
proliferation, invasion, angiogenesis and in vivo tumorigenesis by human HCC cells
(14,18,19,72). Our studies document that SND1 exerts its function in HCC cells by a variety of
mechanisms. SND1 overexpression contributed to increased RISC activity in HCC cells resulting
in augmented degradation of tumor suppressor mRNAs that are target of oncogenic miRNAs
(14). SND1 promotes angiogenesis by activating NF-κB resulting in induction of miR-221 and
subsequently angiogenic factors Angiogenin and CXCL16 (19). SND1 binds to 3’-UTR of
angiotensin II type 1 receptor (AT1R) mRNA, increases AT1R mRNA stability and increases
AT1R protein level (9). We documented that this increase in AT1R by SND1 leads to activation
of ERK, Smad2 and subsequently TGFβ signaling pathway promoting epithelial-mesenchymal
transition (EMT), migration and invasion by human HCC cells (18). SND1 interacts with
monoglyceride lipase (MGLL) resulting in MGLL degradation which leads to activation of Akt
and stimulation of cell proliferation and cell cycle progression in HCC cells (72). Overall, SND1
plays a dynamic role in regulating expression of genes crucial to hepatocarcinogenesis by
employing diverse transcriptional as well as post-transcriptional molecular mechanisms (18,73).
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SND1 is composed of four staphylococcal nuclease (SN) domains and a single fusion
domain, consisting of a tudor domain and a nuclease domain (13). The nuclease domains
function as RNase while tudor domain is involved in protein-nucleic acid interaction (13).
Enzymatic activity of SND1 is required for its function in RISC (8). However, whether the other
functions of SND1 require enzymatic activity remains to be determined. Structurally, SND1 is
unique in the human proteome with no close homolog as revealed by BLAST search (73). The
closest homolog of SND1 is EBNA2, which is not transcribed. SND1 has highly electropositive
SN domains to which binds the negatively charged 3’, 5’-deoxythymidine bisphosphate (pdTp)
molecule inhibiting SND1 nuclease activity (8,13,74,75). The absence of a close homolog of
SND1 and availability of a specific SND1 inhibitor pdTp suggests that pdTp might be developed
as a potential HCC therapeutic with little side-effects. Indeed, we showed that pdTp inhibited
growth of human HCC cells in vitro (14). However, in vivo anti-tumor efficacy of pdTp remains
to be determined. Additionally pdTp might also serve as a valuable tool to distinguish enzymatic
and non-enzymatic functions of SND1.
In the present manuscript we employ a hepatocyte-specific transgenic mouse
overexpressing SND1 (Alb/SND1) to obtain insights into the oncogenic function of SND1 in an
in vivo context. We document that Alb/SND1 mice develop spontaneous HCC with expansion of
tumor initiating cells (TICs). We also demonstrate in vivo safety and anti-tumor efficacy of pdTp
thereby paving the way for its further characterization as an anti-HCC agent. We thus identify
SND1 as a valid molecular target in HCC and present SND1 inhibition as a promising approach
to curb hepatocarcinogenesis.
Materials and Methods
Generation of Alb/SND1 mouse and induction of chemical carcinogenesis
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Alb/SND1 transgenic mouse in B6CBAF1 background was generated by directing the
expression of C-terminal Myc-tagged human SND1 under an upstream enhancer region (–10400
to –8500) fused to the 335-bp core region of mouse albumin promoter (Figure S1) (76).
Microinjection and manipulation procedures were performed according to standard protocols in
the VCU Massey Cancer Center Transgenic/Knockout Mouse Core. For induction of chemical
carcinogenesis, a single i.p. injection of 10 µg/gm body weight of N-nitrosodiethylamine (DEN)
was given at 14 days of age to male WT and Alb/SND1 littermates (77). The animals were
sacrificed at 32 weeks of age and liver, internal organs and blood were collected. Serum liver
enzymes were analyzed in the Molecular Diagnostic Laboratory, Department of Pathology, VCU
using standard procedures. All experiments were performed using sibling littermates, fed regular
chow diet during light cycle. All animal studies were approved by the Institutional Animal Care
and Use Committee at Virginia Commonwealth University, and were conducted in accordance
with the Animal Welfare Act, the PHS Policy on Humane Care and Use of Laboratory Animals,
and the U.S. Government Principles for the Utilization and Care of Vertebrate Animals Used in
Testing, Research, and Training.
Cells, culture condition, sphere formation and Matrigel invasion assays and chemicals
Primary mouse hepatocytes were isolated from adult male WT and Alb/SND1 littermates,
cultured without passage as described and were mycoplasma-free (77). The human HCC cell line
QGY-7703 was developed at Fudan University, Shanghai, obtained from Dr. Zhao-zhong Su in
2008, and cultured as described (58). Generation and characterization of QGY-7703 cells
expressing luciferase (QGY-luc) have been described (78,79). Early passage (>5) cultures of
QGY-7703 and QGY-luc cells were stored in liquid nitrogen and in vivo studies described in this
manuscript were performed with freshly thawed culture of the cells after confirming
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mycoplasma-free using mycoplasma detection kit (ThermoFisher Scientific). Hepatocytes were
cultured in Essential 8 Medium (ThermoFisher Scientific; Catalog # A1517001) for enrichment
of tumor initiating cells using ultra-low attachment plates. Sphere formation was monitored and
spheres containing more than 50 cells were quantified microscopically. Non proliferative spheres
were excluded as abortive spheres. Matrigel invasion assay using primary hepatocytes was
performed as described (58,80). pdTp was purchased from Axxora (Catalog # BLG-T012-05).
BMS-3445541 (Catalog # B9935) and LY294006 (Catalog # L9908) were purchased from
Sigma-Aldrich and U0126 (Catalog # 9903) was purchased from Cell Signaling.
Immunohistochemistry (IHC) and immunofluorescence (IF)
IHC using FFPE sections and IF in primary hepatocytes were performed as described
(58). For IHC, the sections were blocked in PBST using 10% normal goat serum for rabbit and
mouse polyclonal antibodies. Primary antibodies were diluted in PBST containing 5% blocking
serum. The primary antibodies used were: SND1 (rabbit polyclonal; 1:200; Sigma), PCNA
(mouse monoclonal; 1:200; Cell Signaling), AFP (rabbit polyclonal; 1:50; Santa Cruz), F4/80
(rat polyclonal; 1:200; Biorad), CD31 (rabbit polyclonal; 1:50; AbCam), cleaved caspase-3
(rabbit polyclonal; 1:300; Cell Signaling), p-p65 (rabbit polyclonal; 1:400; Cell Signaling),
EpCAM (rabbit polyclonal; 1:400; Sigma), CD133 (rabbit polyclonal; 1:500; Proteintech) and
CD44 (mouse monoclonal; 1:250; AbCam). Biotin conjugated secondary antibodies were diluted
in PBST containing corresponding 2.5% blocking serum. Sections were stained using avidinbiotin-peroxidase complexes treated with a DAB substrate solution (Vector laboratories). IHC
images were quantified by H-score with WT score normalized to 1. For immunofluorescence the
primary antibody was p65 (mouse monoclonal; 1:400; Cell Signaling) and the secondary
antibody was Alexa546-conjugated anti-mouse IgG (goat; 1:400; Invitrogen). The slides were
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mounted in VectaShield fluorescence mounting medium containing 4,6 -diamidino-2phenylindole (Vector Laboratories). Images were analyzed using a Zeiss confocal laser scanning
microscope.
Western Blotting
Lysates were prepared by lysing cells in 1.5% n-dodecyl -D-maltoside (DDM) buffer
supplemented with protease and phosphatase inhibitor cocktail (Pierce). Lysates from liver tissue
were prepared by mechanical homogenization using the same buffer. Western blot was
performed as described (58). Primary antibodies used were SND1 (rabbit polyclonal; 1:1000;
Sigma), GAPDH (mouse monoclonal; 1:1000; Santa Cruz), CD133 (rabbit polyclonal; 1:1000;
Proteintech), CD44 (mouse monoclonal; 1:1000; Abcam), Myc-Tag, p-Akt, Akt, ERK, p-ERK,
p-GSK3 , GSK3 , p-p65, p65 (rabbit polyclonal; 1:1000; Cell Signaling), AT1R (rabbit
polyclonal; 1:1000; Abnova), MGLL (rabbit polyclonal; 1:1000; Thermofisher). Densitometric
analysis was performed by ImageJ software.
Total RNA extraction, cDNA preparation and quantitative RT-PCR
Total RNA was extracted using the QIAGEN miRNAeasy Mini Kit (QIAGEN,
Maryland). cDNA preparation was done using ABI cDNA synthesis kit. Real-time polymerase
chain reaction (RT-PCR) was performed using an ABI ViiA7 fast real-time PCR system and
Taqman gene expression assays according to the manufacturer’s protocol (Applied Biosystems,
Foster City, CA).
Flow cytometry
WT and Alb/SND1 hepatocytes were isolated and washed in PBS. Hepatocytes (1 X 10 6
per sample) were stained with fluorochrome-conjugated primary antibodies in 2% BSA in PBS
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at room temperature for 1 hour. CD133 (mouse-APC; 1:50; Miltenyi Biotec), CD44 (rat-FITC;
1:50; Abcam) and EpCAM (rat-PE; 1:20; BD Pharmingen) were used as per manufacturer’s
protocol. Cells were washed twice in PBS and resuspended in 2% BSA in PBS for flow
cytometric analysis using BD FACSCanto II (San Jose, CA).
Treatment of human HCC xenografts in NSG mice
QGY-7703 cells (6.5 × 105 cells suspended in 50 µl of Matrigel) were injected s.c. in the
flanks of adult male NSG mice. Tumor volume was measured twice a week with a caliper and
calculated using the formula π/6 × larger diameter × (smaller diameter)2. After the tumors have
reached ~100 mm3 (requiring a week) different doses of pdTp (0.16, 0.32 and 0.8 mg/kg) were
administered to the mice i.p. twice a week for 4 weeks. Six mice per group were used for each
treatment group and eight mice were used for control vehicle-treated group. For orthotopic
xenografts, QGY-luc cells (1 × 106) were implanted by intrahepatic injection in adult male NSG
mice (78,79). Tumor growth was monitored by bioluminescence imaging (BLI) with a Xenogen
IVIS imager once a week. After one week, when well-established tumors were detected by BLI,
different doses of pdTp (0.8 and 1.6 mg/kg) were administered to the mice i.v. twice a week for 4
weeks. Six mice per group were used.
Statistical analysis
Data were represented as the mean ± Standard Error of Mean (S.E.M) and analyzed for
statistical significance using student’s paired T-test. A p-value of <0.05 was considered as
significant.
Results
Alb/SND1 mice manifest aggressive hepatocarcinogenesis
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We have created a hepatocyte-specific C-terminal Myc-tagged human SND1-expressing
transgenic mouse (Alb/SND1) by using the mouse albumin promoter/enhancer element to drive
SND1 expression in a B6CBAF1 background (Figure 1A). This particular strain of mouse is very
sensitive to N-nitrosodiethylamine (DEN)-induced hepatocarcinogenesis (77). The expression of
SND1 in the livers of Alb/SND1 mice was confirmed by Western blot, Taqman Q-RT-PCR and
immunohistochemistry (IHC) (Figure 2 A-C, 5A). Alb/SND1 mice develop and reproduce
normally and no physiological abnormalities and significant differences in body weight
compared to WT littermates were observed. Histopathological analysis at 2 months of age did
not reveal any difference in liver architecture between WT and Alb/SND1 mice (Figure 2C).
However, at one year of age, 6 out of 14 (~42%) Alb/SND1 mice developed hepatic nodules,
which were confirmed as HCC upon histological examination with loss of hepatic architecture,
and AFP expression (Figure 2D-F, Table 1). However, no such nodules were observed in WT
littermates. Compared to WT, a significant increase in mRNAs for c-Myc, TNFα and IL-6,
known drivers of HCC, were detected in Alb/SND1 livers at 2 and 12 months of age, except for
IL-6 which showed an increase only at 12 months (Figure 2G).
We next checked the response of Alb/SND1 mice to DEN-induced HCC. At 32 weeks
post DEN-injection, Alb/SND1 mice showed a profound tumorigenic response, with
tumorigenesis affecting the entire liver, compared to WT littermates, in which there were either
no nodules or nodules that were <5 mm in size (Figure 3A, Table 2). Liver weight, reflecting
higher tumor load, and serum AST, ALT and total protein were significantly elevated in
Alb/SND1 mice versus WT (Figure 3B-C). A marked increase in mRNA of HCC markers AFP
and CD36 were detected in DEN-treated Alb/SND1 livers compared to DEN-treated WT (Figure
3D). Histologically DEN-treated Alb/SND1 livers showed loss of architecture and increased
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expression of CD31 (angiogenesis marker) and PCNA (proliferation marker) vs DEN-treated
WT (Figure 3E, 5A). Increased activation of ERK, Akt and its downstream GSK3β was observed
in DEN-treated and spontaneous Alb/SND1 tumors compared to DEN-treated WT (Figure 3F,
5B). ERK and Akt are activated by SND1 (18,72) and also play critical role in HCC (81) thus
might be crucial in mediating SND1-induced HCC.
Alb/SND1 hepatocytes show increased activation of NF-κB
Chronic inflammation is a central event in hepatocarcinogenesis and NF-κB plays a
pivotal role in promoting inflammation (82). Increased expression of IL-6 and TNFα (Figure 2G)
indicates that SND1 overexpression results in a chronic inflammatory state leading to HCC. We
previously documented activation of NF-κB in SND1-overexpressing human HCC cells (19).
NF-κB activation is marked by phosphorylation of serine residue 536 allowing nuclear
translocation of p65 subunit, which then functions as a transcription factor to modulate
expression of inflammatory genes. We checked nuclear localization of p65 NF-κB in WT and
Alb/SND1 hepatocytes, treated or not with lipopolysaccharide (LPS), since serum LPS levels are
elevated in HCC patients which promotes inflammation. Alb/SND1 hepatocytes, but not WT,
showed nuclear p65 under basal condition indicating constitutive activation of NF-κB (Figure
4A). LPS treatment resulted in nuclear translocation of p65 in both WT and Alb/SND1
hepatocytes. Inhibition of enzymatic activity of SND1 by pdTp resulted in marked
downregulation of p65 levels with simultaneous inhibition of p65 nuclear translocation in both
WT and Alb/SND1 hepatocytes suggesting a central role of SND1 in regulating p65 expression
(Figure 4A). Western blot analysis revealed increased basal level of phosphorylated p65 (p-p65)
in Alb/SND1 hepatocytes compared to WT (Figure 3B). In WT hepatocytes, upon LPS
treatment, increased p-p65 was observed at 10 minutes which gradually waned down over a
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period of 2 h (Figure 4B). However, in Alb/SND1 hepatocytes increased p-p65 level remained
sustained during the assay period (Figure 4B). Increased inflammation was also indicated by
increased infiltration of macrophages, detected by staining for F4/80 marker, in DEN-treated and
one year old tumor-bearing Alb/SND1 livers versus corresponding WT (Figure 4C, 5C).
Additionally a marked increase in immune checkpoint molecule PD-L1 and a significant increase
in its receptor PD-1 were observed in DEN-treated and one year old tumor-bearing Alb/SND1
livers vs corresponding WT indicating a strong carcinogenic response induced by SND1
overexpression (Figure 5D).
SND1 overexpression results in expansion of tumor initiating cells (TICs)
Since Alb/SND1 mice develop spontaneous HCC, we checked the effect of SND1
overexpression on TICs. In a sphere formation assay in ultra-low attachment plates, WT
hepatocytes formed small abortive spheres while Alb/SND1 hepatocytes formed robust spheres
that gradually increased in size and number indicating an expansion of tumor initiating cells
(TICs) (Figure 6A). Indeed, TICs positive for three markers, EpCAM, CD44 and CD133, were
significantly more in Alb/SND1 livers versus WT (Figure 4B). Alb/SND1 hepatocytes isolated
from 2 months old mice showed significant increase in mRNA levels of EpCAM (~ 2-fold),
CD44 (~4-fold) and CD133 (~4-fold) compared to WT (Figure 7A). These increases in mRNA
levels were further augmented, e.g., EpCAM (~2.5-fold), CD44 (~6-fold) and CD133 (~4-fold),
in Alb/SND1 hepatocytes isolated from 12 months old mice versus WT (Figure 7A).
Immunohistochemical analysis showed increased expression of EpCAM, CD44 and CD133 in
one year old Alb/SND1 livers, with or without tumor, compared to WT littermates (Figure 7BC). Increased CD133 expression was observed in DEN-treated and spontaneous tumors in
Alb/SND1 mice when compared to DEN-treated WT livers (Figure 7D). Treatment with pdTp
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significantly inhibited sphere formation by both WT and Alb/SND1 hepatocytes indicating that
enzymatic function of SND1 is necessary to promote expansion of TICs (Figure 6C). As
expected from studies in human cell lines, naïve Alb/SND1 livers showed increased activation of
ERK and Akt (Figure 6D). To check the effects of the signaling pathways activated by SND1 in
regulating TICs we performed sphere formation assay with Alb/SND1 hepatocytes upon
treatment with BMS-3445541(IκB kinase inhibitor to block NF-κB activation), LY294006 (PI3K
inhibitor to block Akt activation) and U0126 (MEK1/2 inhibitor to block ERK activation)
(Figure 6E-F). Inhibition of NF-κB and Akt activation, but not ERK activation, significantly
abrogated sphere formation by Alb/SND1 hepatocytes with corresponding decrease in CD133
expression (Figure 6E-F, 10A). We interrogated the potential role of ERK activation in SND1induced phenotypes other than sphere formation. We previously demonstrated a potential role of
ERK activation in mediating SND1-induced invasion of human HCC cells (18). While WT
hepatocytes did not invade through Matrigel, Alb/SND1 hepatocytes acquired Matrigel invasion
property which was significantly abrogated upon treatment with U0126 (Figure 6G).
SND1 inhibitor pdTp significantly abrogates human HCC xenografts in vivo:
pdTp specifically inhibits the nuclease activity of SND1, but does not affect the
oligonucleotide binding function of Tudor domain. We previously documented that pdTp inhibits
proliferation of human HCC cells in vitro (14). As yet in vivo efficacy and toxicity has not been
tested for pdTp. We injected multiple doses of pdTp (calculated from our in vitro studies) to WT
B6CBA mice i.p. twice a week for 4 weeks (a total of 8 doses). At the highest dose of 0.8 mg/kg,
no difference in body and liver weights, serum liver enzymes, total protein, albumin and globulin
was observed vs vehicle at the end of the treatment cycle (Figure 8A-B). Bilirubin levels
(conjugated and unconjugated) were normal and did not show any increase upon pdTp treatment
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(<0.1 units/dL, each). Histological analysis of internal organs also did not show any abnormality
(Figure 8C). We established s.c. xenografts of QGY-7703 cells in NSG mice and evaluated the
effect of i.p. administration of different doses pdTp on tumor development. A significant
decrease in tumor volume and tumor weight was observed with 0.32 and 0.8 mg/kg pdTp at the
end of the treatment (Figure 8D). We next established orthotopic xenografts of QGY-luc cells
(QGY-7703 cells expressing luciferase) in the livers of NSG mice and evaluated the effect of i.v.
administration of pdTp on tumor development by bioluminescence imaging (BLI). A significant
inhibitory effect on tumor progression was observed with pdTp treatment compared to vehicle
(Figure 8E-F). Immunohistochemical analysis of s.c. tumor sections revealed that pdTp treatment
resulted in a dose-dependent decrease in PCNA, CD133, CD44 and p-p65 staining, and an
increase in apoptosis, determined by staining for cleaved caspase 3 (Figure 9A, 10B). Western
blot analysis of tumor samples identified that pdTp treatment resulted in downregulation of
CD133 and CD44 levels and decreased phosphorylation of Akt and p65 (Figure 9B, 10C). Total
p65 level was also decreased upon pdTp treatment (Figure 9B). Interestingly, no change in ERK
activation was observed upon treatment with pdTp. We previously documented that increased
RISC activity resulting from SND1 overexpression augments oncomiR-mediated degradation of
tumor suppressor mRNAs, such as PTEN, target of miR-221 and miR-21, CDKN1C (p57), target
of miR-221, CDKN1A (p21), target of miR-106b, SPRY2, target of miR-21, and TGFBR2,
target of miR-93 (14). As a corollary, in vivo pdTp treatment resulted in significant increases in
PTEN, TGFBR2 and CDKN1C mRNA levels in tumors compared to vehicle (Figure 9C).
Collectively, these findings reveal that pdTp inhibits proliferation and inflammation, induces
apoptosis and downregulates tumor initiating cells.
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Discussion
In this research article, we report oncogenic role of SND1 in HCC development and
progression by pursuing studies in a novel hepatocyte-specific SND1-overexpressing transgenic
mouse model. Our previous in vitro studies established that SND1 overexpression positively
regulates multiple hallmarks of cancer, including proliferation, migration, invasion,
angiogenesis, epithelial-mesenchymal transition and inhibition of tumor suppressor gene
expression (14,18,19,72). In the current in vivo studies, we document that SND1 causes
spontaneous hepatocarcinogenesis by increasing TICs within the liver and creating a proinflammatory microenvironment, and sensitizes hepatocytes towards DEN-induced HCC. As a
corollary, chemical inhibition of SND1 enzymatic activity by pdTp reduced tumor-initiating
potential of hepatocytes and rescued pro-inflammatory signaling caused by SND1
overexpression resulting in significant abrogation of tumor growth in a xenograft model.
SND1 is a multifunction protein that regulates gene expression at transcriptional as well
as post-transcriptional level. Inflammatory cytokine TNFα is constitutively upregulated in
Alb/SND1 liver, whereas IL-6 is upregulated in an age-dependent manner. Both these cytokines
are known to activate NF-κB signaling and are also induced by NF-κB. As expected, Alb/SND1
hepatocytes manifest an exaggerated NF-κB activation, both constitutive and upon LPS
treatment. LPS is detected at notably high levels in HCC patients, thus making SND1-mediated
augmentation in NF-κB activation a clinically relevant scenario. Activation of resident Kupffer
cells and invasion of liver with macrophages is a crucial event in HCC. Secretion of
inflammatory cytokines by SND1-overexpressing hepatocytes might contribute to NF-κB
signaling and activation in macrophages. Thus, SND1 overexpression creates an underlying pro-
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inflammatory condition within liver, which aggravates with age, creating conducive preexisting
pathology for tumorigenesis.
We observe that constitutive overexpression of SND1 predisposes Alb/SND1 animals to
risk of HCC development in late adulthood, in the absence of any carcinogen exposure, with
expansion of CD133+, CD44+ and EpCAM+ TICs. Our inhibitor studies unravel that active Akt
and NF-κB signaling is required to maintain tumor initiation potential of SND1 overexpressing
hepatocytes. A recent report documented that in a hepatitis B model, AFP-induced upregulation
of CD133+, CD44+ and EpCAM+ TICs is dependent on PI3K/Akt signaling (83). Clinical study
analyzing protein marker expression in liver from more than 100 HCC patients showed a
significant negative correlation with PTEN and positive correlation with Akt levels with TIC
marker proteins CD133, EpCAM and CD90 (84). Univariate and multivariate analysis showed
significant correlation between loss of PTEN and high AFP, Akt, CD133 and EpCAM levels
with overall survival of HCC patients (84). CD133 expression is correlated with Sorafenib
resistance in human HCC patients (85,86). CD133 confers chemoresistance and radioresistance
via upregulation of PI3K/AKT signaling (86,87). Interaction between hyaluronan and CD44 in
extracellular matrix promotes carcinogenic signaling and results in chemoresistance (88). Thus a
close interplay between AKT signaling and TIC expansion is predicted in Alb/SND1 livers
rendering them therapeutically resistant. It would be interesting to investigate potential of SND1
targeting in overcoming chemoresistance in HCC for future studies.
Studies have shown that IL-8, a NF-κB downstream gene, increases CXCL1 expression,
upregulates MAPK signaling and sustains cancer stemness that eventually expands CD133+
population in liver (89). Autocrine IL-6 signaling is also implicated in pro-tumorigenic
properties of HCC progenitor cells (90). IL-6 signaling promoted by tumor-associated
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macrophages is found to promote expansion of CD44+ cells, potentiating growth of xenograft
tumors, and inhibition of IL-6/STAT3 signaling in this model, reduced tumorigenic potential of
CD44+ cells (91). In SND1 overexpressing HCC, we report an increased invasion of
macrophages, which can be predicted to upregulate IL-6 secretion and thus promote expansion of
TICs. As yet the molecular mechanism by which SND1 activates NF-κB remains to be
determined. pdTp treatment studies clearly demonstrate that SND1 enzymatic activity is required
to activate NF-κB (Figure 3A). However, pdTp treatment also resulted in a decrease in total p65
level indicating that SND1 regulates not only NF-κB activation but also p65 expression.
Inflammatory cytokines induce SND1 expression and SND1 promoter contains consensus NFκB binding sites (29,92). Thus chronic inflammation preceding HCC might result in induction of
SND1 which facilitates expansion of TICs and further aggravates inflammation thereby
establishing a scenario for the development of HCC.
SND1 overexpression activates Akt, ERK and NF-κB signaling. We document that pdTp
treatment inhibited Akt and NF-κB activation but not ERK activation in human HCC cells
(Figure 9B) and inhibited sphere formation by WT and Alb/SND1 hepatocytes (Figure 6C).
Additionally inhibition of Akt and NF-κB, but not that of ERK, abrogated sphere formation by
Alb/SND1 hepatocytes (Figure 6E-F). These findings suggest that enzymatic activity of SND1 is
necessary for expansion of TICs and is not necessary for ERK activation. Binding of SND1 to
3’-UTR of AT1R mRNA increases AT1R mRNA stability and protein translation resulting in
increased ERK activation (9,18). This function of SND1 does not require its enzymatic activity
and is not inhibited by pdTp treatment. SND1 activates Akt by multiple mechanisms. By
augmenting RISC activity it downregulates PTEN, a negative regulator of Akt signaling (14).
Protein-protein interaction between SND1 and MGLL results in MGLL degradation (72). MGLL
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selectively interacts with phosphatidic acid and phosphoinositide derivatives leading to inhibition
of PI3K/Akt signaling (93). As such MGLL degradation results in Akt activation. SND1
interacts with MGLL via its SN domains to which pdTp binds (72). pdTp might interfere with
SND1/MGLL interaction thereby blocking Akt activation. Thus SND1-induced Akt activation
requires enzymatic and non-enzymatic activities of SND1 both of which might be interfered by
pdTp. It should be noted that downregulation of MGLL and upregulation of AT1R are also
preserved in Alb/SND1 livers compared to WT (Figure 11).
We present SND1 inhibition as a new avenue for targeted therapeutic research in HCC
management. The non-toxicity, specificity for SND1 inhibition and strong therapeutic efficacy
make pdTp an attractive reagent for clinical use. More stringent pharmacokinetic and
biodistribution studies and medicinal chemistry analysis to generate more potent pdTp analogs
should be pursued further. However, pdTp may not block all aspects of SND1 function,
especially its non-enzymatic function, thereby requiring an alternative approach to inhibit SND1.
We have recently demonstrated therapeutic utility of a hepatocyte-specific nanoparticle
delivering siRNA against an oncogene in orthotopic xenograft models of HCC (78). Similar
approaches might be employed to knockdown SND1 and in combination with pdTp might bring
forth complete and sustained inhibition of SND1 function. These approaches might also be
combined with current standard of care chemotherapies for HCC. Our present study opens up a
wide avenue of preclinical and clinical research on testing efficacy of a novel targeted treatment
approach.
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Figure 1. Generation of Alb/SND1 mice. A. Alb/SND1 transgene. The 6.9-kb Alb/SND1
transgene contains, in order, a 2.3-kb mouse Alb1 enhancer/promoter, a 0.7-kb rabbit

-globin

intron, the 2.7-kb human SND1 ORF, C-terminal MYC and FLAG tags, and a 0.6-kb human
GH1 polyadenylation region. Translational start and stop codons and EcoRV sites are indicated.
B. PCR screening. The five potential Alb/SND1 founders were set up with B6CBAF1 mates, and
genomic tail DNA from their offspring was screened for the presence of the Alb/SND1 transgene
by a PCR protocol. The protocol utilizes a rabbit -globin intron 2 sense primer (5’GATATACACTGTTTGAGATGAGG-3’) in combination with a human SND1 ORF anti-sense
primer (5’-CTATCGTGAAACAGACTTCCTTCC-3’), and generates a 487-bp PCR product in
mice carrying the transgene. Four of the five founders transmitted the transgene to their progeny,
with two of the four resulting lines each possessing two transgene integration sites, which were
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then resolved by Southern blot analysis. A PCR screening of offspring from founder #3 is
shown. C. Southern blot analysis. Genomic tail DNA from the five PCR-positive offspring of
founder #3 (shown in B) was digested with EcoRV and electrophoresed on a 0.9% agarose gel
along with 1 kb DNA Ladder markers. The 6.9-kb Alb/SND1 transgene was used as both probe
and 10X copy number control. Lines 3a (#2 and #4) and 3b (#1, #3, and #6) both possess a 3391bp junction (J) fragment (2491 bp + 900 bp), indicative of a head-to-tail array, as well as the
expected 3217-bp and 330-bp (not shown) internal fragments. Southern blot analysis of PCRpositive offspring from all Alb/SND1 founders identified a total of six separate lines, which were
then assessed for hepatocyte-specific expression of human SND1 by Western blot analysis.
SND1 expression was determined to be greatest in line 3a, and it was therefore the line used in
this study.
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Figure 2. SND1 overexpression in vivo results in neoplastic transformation. SND1
overexpression in Alb/SND1 (TG) liver was confirmed by Western blot (A), Taqman Q-RT-PCR
(B) and immunohistochemistry (C). SND1 mRNA levels were normalized by GAPDH mRNA
levels. For A-C, liver samples from 2 months old mice were used. D. Photographs of
representative livers of one year old mice. Arrow indicates liver nodule. E. Histological analysis
and AFP immunostaining of FFPE liver sections from one year old Wildtype (WT) and
Alb/SND1 mice with or without tumors. F. Relative expression of AFP mRNA by Taqman Q-
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RT-PCR in one year old WT and Alb/SND1 mice with tumor (3 mice per group). G. Relative
expression of the indicated mRNAs by Taqman Q-RT-PCR in livers of 2 months and one year
old mice (3 mice per group). For graphs, data represent mean ± SEM; *: p<0.01 vs WT.
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Figure 3. Alb/SND1 mice develop aggressive DEN-induced HCC. WT and Alb/SND1
littermates were injected i.p. with DEN (10µg/gm) at 2 weeks of age and livers were harvested at
32 weeks post-injection when subsequent analyses were performed. A. Photographs of
representative livers. Measurement of liver wt (B), and serum AST, ALT and total protein (C)
(WT: n = 8; Alb/SND1: n = 10). D. Analysis of AFP and CD36 mRNA levels by Taqman Q-RTPCR in naïve and DEN-treated livers. Normalized by GAPDH. E. Histological analysis and IHC
for CD31 and PCNA in FFPE liver sections. F. Western blot analysis for the indicated proteins in
the livers of DEN-treated WT and Alb/SND1 littermates at 32 weeks and spontaneous tumors in
Alb/SND1 livers at one year. For graphs, data represent mean ± SEM; *: p<0.01 vs WT.
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Figure 4. NF-κB activation is exaggerated in Alb/SND1 hepatocytes. A. Hepatocytes were
harvested from one year old WT and Alb/SND1 littermates and treated with LPS (200 ng/ml) for
30 minutes. In a second experiment, hepatocytes were treated with pdTp (200 µM) for 18 h
before LPS treatment. The hepatocytes were immunostained for p65 NF-κB and
immunofluorescence analysis was performed by confocal microscopy. B. Hepatocytes were
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harvested from 2 months old WT and Alb/SND1 littermates and treated with LPS (200 ng/ml)
for the indicated time points. Western blot analysis of the indicated proteins was performed. C.
FFPE sections of DEN-treated and one year old WT and Alb/SND1 livers were stained for
macrophage marker F4/80.
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Figure 5. SND1 overexpression strongly induces HCC markers. A. Quantification of the IHC
images corresponding to Figure 1C, 1E and 2E by H-score. WT levels were normalized to 1. B.
Densitometric analysis of p-AKT/AKT, p-GSK3β/GSK3β and p-ERK/ERK ratios in the
indicated samples corresponding to Figure 2F. C. Quantification of F4/80 staining in the
indicated samples corresponding to Figure 3C by H-score. WT levels were normalized to 1. D.
Relative expression level of PD-L1 and PD-1 mRNAs by Taqman QRT-PCR in DEN-treated
Alb/SND1 (TG) livers and one year old tumor-bearing Alb/SND1 livers compared to
corresponding WT (3 mice per group). Data represent mean ± SD of three independent
experiments. *: p<0.01.
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Figure 6. SND1 overexpression results in expansion of tumor initiating cells (TICs). A.
Hepatocytes were harvested from one year old WT and Alb/SND1 littermates and cultured under
ultra-low attachment conditions to form spheroids and observed over a period of 3 days. Left
panel, photomicrograph of representative spheres. Right panel, graphical quantification of the
spheres. B. Hepatocytes were harvested from one year old WT and Alb/SND1 littermates,
immunostained with fluorochrome-conjugated EpCAM, CD44 and CD133 antibodies and
subjected to flow cytometry. C. Hepatocytes were harvested from 2 months old WT and
Alb/SND1 littermates, treated with pdTp (200 µM) and sphere formation was measured over a
period of 7 days. D. Western blot analysis of the indicated proteins in the livers of one year old
WT and Alb/SND1 littermates. Two independent mice per group were used. E-F. Hepatocytes
from 2 months old Alb/SND1 mice were harvested and treated with BMS-3445541(5µM),
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LY294006 (25µM) and U0126 (10µM) in enriching conditions. Western blot analysis using the
indicated antibodies was performed (E). Sphere formation was compared between untreated and
treated Alb/SND1 hepatocytes over a period of 3 days (F). G. Matrigel invasion using WT and
Alb/SND1 (TG) hepatocytes treated or not with U0126 (10 µM) was performed. HPF: high
power field. For graphs, data represent mean ± SEM; *: p<0.01 vs WT in panel A and G, Vehicle
(Veh) in panel C and No Rx in panel F.
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Figure 7. SND1 overexpression increases TIC markers. A. Relative expression of the
indicated mRNAs by Taqman Q-RT-PCR in livers of 2 months and one year old mice. Data
represent mean ± SEM; *: p<0.01 vs WT. B. Immunostaining of the indicated proteins in FFPE
liver sections from one year old Wildtype (WT) and Alb/SND1 mice with or without tumors. C.
Quantification of IHC images corresponding to Figure S3B by H-score. WT levels were
normalized to 1. Data represent mean ± SEM; *: p<0.01 vs WT. D. Western blot analysis for the
indicated proteins in the livers of DEN-treated WT and Alb/SND1 littermates at 32 weeks and
spontaneous tumors in Alb/SND1 livers at one year.
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Figure 8. pdTp is non-toxic and inhibits human HCC xenografts. WT B6/CBA mice (2
months old) were injected i.p. with 0.8 mg/kg pdTp twice a week for 4 weeks. Body and liver
weights (A), and serum liver enzymes (AST, ALT and AP), total protein (TP), albumin (Alb)
and globulin (Glo) (B) were measured at the end of the treatment. C. Histology of internal organs
at the end of pdTp treatment. D. QGY-7703 cells were injected s.c. in NSG mice to establish
xenografts and treated with the indicated doses of pdTp i.p. twice a week for 4 weeks (n = 6 per
dose). Tumor volume and weight were measured at the end of the treatment. E-F. QGY-luc cells
were injected orthotopically in the livers of NSG mice to establish xenografts and treated with
the indicated doses of pdTp i.v. twice a week for 4 weeks (n = 6 per dose). Bioluminescence
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imaging (BLI) of the orthotopic tumors before and after pdTp treatment (E). Quantification of
photon counts from the mice (F). For graphs, data represent mean ± SEM; A, B and D: *: p<0.01
vs pdTp 0 mg/kg; F: *: p<0.05 vs pdTp 0 mg/kg After Rx.
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Figure 9. pdTp reduces expression of proliferation, inflammation and TIC markers, and
upregulates apoptosis and expression of selective tumor suppressor genes. A. FFPE sections
of vehicle- and pdTp-treated s.c. xenograft tumors were analyzed histologically and
immunostained for the indicated proteins. B. Western blot analysis of the indicated proteins in
vehicle- and pdTp-treated s.c. xenograft tumor samples. Tumor samples from two independent

52

mice per group were used. C. Relative expression of the indicated mRNAs was measured by
Taqman Q-RT-PCR in vehicle- and pdTp-treated s.c. xenograft tumors (3 mice per group).
Normalized by GAPDH. Data represent mean ± SEM; *: p<0.01.
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Figure 10. Quantification of Western Blots and Immunohistochemistry. A. Densitometric
analysis of CD133 levels corresponding to Figure 4E. B. Quantification of the indicated IHC
images corresponding to Figure 6A by H-score. WT levels were normalized to 1. C.
Densitometric analysis of the indicated protein ratios corresponding to Figure 6B. Data represent
mean ± SEM; *: p<0.01 vs untreated.
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Figure 11. MGLL is downregulated and AT1R is upregulated in Alb/SND1 livers. A.
Representative image of Western blot analysis of the indicated proteins. B. Densitometric
analysis of MGLL and AT1R levels corresponding to Figure S5A. Data represent mean ± SEM;
*: p<0.01 vs WT.
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Post-transcriptional inhibition of Protein tyrosine phosphatase, non-receptor type 23 by
Staphylococcal nuclease and tudor domain containing 1
Introduction
Staphyloccocal nuclease and tudor domain containing 1 (SND1) has been identified as an
oncogene and potential molecular target in multiple cancers including breast (16), prostate (20),
colorectal (21), glioblastoma (71) and hepatocellular carcinoma (HCC) (14,94). In the context of
HCC, we generated and characterized a transgenic mouse with liver-specific overexpression of
SND1 (Alb/SND1) which developed spontaneous HCC with variable penetrance thereby
establishing SND1 as a bona fide driver oncogene (94). It was demonstrated that SND1
overexpression resulted in expansion of tumor initiating cells (TIC) and created a proinflammatory milieu by activation of NF- B thereby facilitating development of HCC (94).
SND1 protein structure comprises of five independent motifs: four repeats of Staphylococcal
nucleases (SN) and a fusion motif of tudor and SN domains. Tudor domains have been
structurally characterized to allow protein-protein and protein-oligonucleotide interactions (13).
SNs function as RNase and can be inhibited by the specific chemical inhibitor 3’, 5’deoxythymidine bisphosphate (pdTp) (95). SND1 regulates gene expression at transcriptional as
well as post-transcriptional levels (73). In prostate cancer, SND1 promotes alternative splicing of
oncogenic splice variant of CD44 (47). In HCC, SND1 is a functional RNase in RNA induced
silencing complex (RISC) where it regulates microRNA mediated gene expression in a protumorigenic manner (14). SND1 can also bind to mRNA transcripts to increase its stability and
translation efficiency, as demonstrated by its interaction with angiotensin II type 1 receptor
(AT1R) (9). In HCC, this interaction promotes ERK activation and TGFβ signaling, thereby
significantly increasing angiogenesis and epithelial-mesenchymal transition (EMT) (18).
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We demonstrated that pdTp markedly inhibits in vitro and in vivo growth of human HCC cells
indicating that enzymatic activity of SND1 plays an important role in mediating its oncogenic
function (14,94). To obtain a comprehensive insight into the RNA targets of SND1 we focused
on identifying SND1 RNA interactome which unraveled Protein tyrosine phosphatase, nonreceptor 23 (PTPN23, HD-PTP) to be a major target of SND1.
PTPN23 was identified as an inhibitor of Ha-Ras-mediated transformation of cardiomyocytes
(96) and characterized as a tumor suppressor in testicular cancer (97) and breast cancer (98).
Genetic deletion of PTPN23 is non-viable and loss of heterozygosity results in c-myc driven B
cell lymphoma and lung adenoma (99). PTPN23 is a functional component of endosomal sorting
cargo trafficking complex (ESCRT) (100) and thus facilitates lysosomal degradation of EGFR
and PDGFR (101,102). PTPN23 inhibits endothelial migration via inhibition of Src kinase (103)
and Focal adhesion kinase (104).
Although PTPN23 has been identified as a potential tumor suppressor its role in HCC has not
been investigated. In this study we analyzed the mechanism of PTPN23 regulation by SND1 and
unraveled molecular and phenotypic changes upon PTPN23 overexpression.
Experimental Procedures
RNA immunoprecipitation sequencing (RIP-Seq)
RNA immunoprecipitation using lysates from QGY-7703 cells and control IgG and anti-SND1
antibody (rabbit polyclonal; Prestige Antibodies® Powered by Atlas Antibodies from Sigma,
HPA002632) was performed using Magna RIP RNA Binding Protein Immunoprecipitation kit
(Millipore) according to the manufacturer’s protocol and RNA was extracted from the
immunoprecipitates using a miReasy kit (QIAGEN). Independent RNA samples, 3 from control
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IgG and 5 from anti-SND1 antibody, were subjected to RNA-seq. All samples were aligned with
their reference genome (UCSC-hg19) using TopHat2 and the Bam files from alignment were
processed using HTSeq-count to obtain the counts per gene. The counts were read into R
software using DESeq package and plot distributions were analyzed using Reads Per Kilobase
Million (RPKM) values. Pairwise tests were performed between control IgG and anti-SND1
antibody. Data were filtered based on low count or low RPKM value (<45 percentile).
Cell culture and cloning
Primary human hepatocytes, Hc3716-hTERT and human HCC cells were cultured as described
(58,77,105). Generation and characterization of SND1 overexpressing clones of Hep3B cells and
SND1 knockdown clones of QGY-7703 cells were described previously (14). Tetracyclineinducible PTPN23 overexpressing clones in QGY-7703 and HepG3 cells were created using TRex system (Invitrogen). Full length human PTPN23 ORF was obtained from Origene, amplified
by PCR using a 5’ primer containing HindIII site and Kozak sequence along with a 3’ primer
containing an XhoI site, and cloned into pcDNA4/TO/myc-His plasmid (Invitrogen, K1030-01).
Both cell lines were transfected with pcDNA6/TR plasmid, which encodes the Tet repressor
(TetR), and pcDNA4-PTPN23. QGY-7703 clones were selected using 90µg/ml zeocin and
30µg/ml blasticidin for 2-3 weeks. HepG3 clones were selected with 30µg/ml zeocin and
10µg/ml blasticidin for 2-3 weeks. QGY clones were maintained on 30µg/ml zeocin and
10µg/ml blasticidin whereas HepG3 clone were maintained on 10µg/ml zeocin and 5µg/ml
blasticidin in DMEM with 10% fetal bovine serum. 4µg/ml of tetracycline was used for inducing
PTPN23 expression. HCC cell lines were treated with 200µM of pdTp for 24 hours.
RNA gel shift assay
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PTPN23 full length and 3’-UTR were cloned into pGEM-T Easy vector by 3’-T end ligation. 32P-labeled UTP from Perkin Elmer was used in MAXIScript Kit (Ambion, AM1308-AM1326)
along with these plasmids to generate in vitro transcribed RNA as per manufacturer’s protocol.
Radiolabeled transcripts were separated and purified on 4% non-denaturing gel. SND1 protein or
non-specific control protein (MMP-9) were synthesized in vitro using TNT T7 Quick Coupled
Transcription/ Translation Systems (Promega, L1171). In vitro translated protein was incubated
with purified radiolabeled transcript at 37°C and 4°C. Reaction mixtures were separated on a 4%
non-denaturing gel using Tris-Boric Acid-EDTA buffer (National Diagnostics, LC-860). The gel
was dried on filter paper and exposed to autoradiography.
RNA Degradation Assay
Total RNA was purified from QGY-7703 cells using QIAGEN miReasy kit. In vitro translated
SND1 protein was incubated with 10μg RNA, at 37°C for 15 min, 30 min, 1 hour and 2 hours. In
vitro translated non-specific protein control (MGLL) was incubated with 10μg of RNA at 37°C
for 2 hours. RNA was purified from each reaction mixture using QIAGEN miReasy kit. cDNA
library was synthesized using cDNA synthesis kit (Life Technologies). BCAM, LAMB3 and
PTPN23 mRNA levels were measured by real time PCR using an ABI ViiA7 fast real time PCR
system and Taqman gene expression assays according to the manufacturer’s protocol (Applied
Biosystems).
Human Phospho-RTK Array
Human phospho-RTK array was performed with the Proteome ProfilerTM Array kit (R&D
Systems, Inc, Minneapolis, MN) using 500µg cell lysates according to the manufacturer’s
instructions.
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Migration Assay
Cells were plated, grown to confluency and scratched with a 200µl micropipette tip to create a
cell-free wound area. Images were captured at 0 and 24 hours after wounding using an Olympus
IX-50 microscope. Cell migration distance was determined by measuring the scratch width at
three randomly selected locations in the wound area. Decrease in wound width is indicative of
distance migrated by cells. 4µg/ml of tetracycline was used to induce PTPN23 expression.
Comparison was made between scratch width in un-induced and induced clones after 24 hours.
Invasion Assay
PTPN23 expression was induced with 4µg/ml of tetracycline for 48 hours. 2 X 104 of induced
and un-induced cells were plated on activated Matrigel chamber as described (58). Cells
invading the Matrigel were fixed and stained after 22 hours, as per the manufacturer’s protocol.
Invaded cells were observed and quantified microscopically.
Colony formation assay
For colony formation assay, 500 cells were plated in triplicates and cultured with or without
4µg/ml of tetracycline for 2 weeks. Foci were fixed with 3.7% formaldehyde for 10 minutes and
stained with Giemsa. Foci were quantified and compared between induced and un-induced
clones.
Protein extraction and Western Blotting
Protein lysates were prepared by lysing cells with 1.5% sodium dodecyl sulphate buffer and
separated on 4-12% gels. Western blotting was performed as described (58). Polyclonal primary
antibodies against SND1 (Sigma Aldrich, HPA002632), PTPN23 (Proteintech, 10472-1-AP) and
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pFAK, FAK, pSrc (#2101), Src (#2109), pMet (#3077), Met (#3127), pEGFR (#2234), EGFR,
pERK, ERK, p-β-catenin (#9561), β-catenin, Vimentin (#5741), N-cadherin (#4061), Slug
(#9585), Snail (#3879) from Cell Signaling were incubated in 5% BSA at recommended dilution.
GAPDH (Santa Cruz, sc166545) was incubated in 5% milk at 1:1000 dilution.
Immunohistochemistry
Formalin fixed paraffin embedded tissue sections or tissue microarray for human HCC were
deparaffinized, blocked in 5% goat serum and immunostained with primary antibodies against
PCNA (Cell Signaling), Cleaved Caspase 3 (Cell Signaling) and PTPN23 (Sigma Aldrich,
HPA016845). Biotinylated secondary antibodies from Vector laboratories were used in 2.5%
goat serum. Immunostained tissue sections and tissue array were stained with DAB substrate and
hematoxylin for visualization.
Immunofluorescence (IF)
IF was performed in primary human hepatocytes and QGY-7703 cells using polyclonal rabbit
anti-PTPN23 antibody (ProteinTech, 10472-1-AP) with anti-rabbit secondary antibody (Dako,
#P045). To stain actin cytoskeleton rhodamine phalloidin (ThermoFisher, #R415) was used
according to the manufacturer’s protocol. The slides were mounted in Vectashield fluorescence
mounting medium containing 4, 6-diamidino-2-phenylindole (Vector Laboratories). Images were
analyzed using a Zeiss confocal laser scanning microscope.
RNA extraction, cDNA synthesis, quantitative real time PCR and Reverse Transcriptase
PCR
RNA was extracted from cells or tissue using Qiazol and miReasy kit (QIAGEN). cDNA library
was synthesized using cDNA synthesis kit (Life Technologies). Real time PCR was performed
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using an ABI ViiA7 fast real time PCR system and Taqman gene expression assays according to
the manufacturer’s protocol (Applied Biosystems). For Reverse Transcriptase PCR, primer
spanning 200-300bp region on cDNA of target gene were used. Primer information is provided
in Table 4.
Xenograft study
1 X 106 cells of each QGY-Rep-Pt5, QGY-Rep-Pt6 and parental QGY-7703 cell line were
suspended in 50μl of sterile phosphate buffered saline, mixed with 50μl of Matrigel and injected
subcutaneously in flanks of 2-3 months old male NSG mice. Macroscopic tumors were observed
after 4 days. Test group of mice was fed doxycycline containing chow (ENVIGO, #2919) and
control group of mice was fed regular chow. Tumor dimensions were measured using Vernier
caliper twice a week, for up to 4 weeks. Tumors were harvested and tumor weights were
measured. Tumor volume was measured using (Width)2  length/2 formula.
Statistical Analysis
Student’s T-test was used to determine significance (p-value) for comparisons between control
(uninduced) and test (induced) groups at α = 0.05.
Results
RNA immunoprecipitation sequencing (RIP-Seq) identifies PTPN23 as an SND1
interacting mRNA
To identify SND1 RNA interactome, we immunoprecipitated and purified RNAs from lysates of
QGY-7703 cells (that endogenously overexpress SND1) using control IgG and anti-SND1
antibody (Figure 1A). Independent RNA samples, 3 from control IgG and 5 from anti-SND1
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antibody, were subjected to RNA-sequencing. Using an adjusted p-value of <0.01, average
expression level >0 (log2 transformed RPKM level) and 2-fold higher than control, 282
transcripts were found to interact with SND1 (Figure 1B). We focused on those genes that show
significant changes with >10-fold enrichment in SND1 group over control and have relevance to
cancer pathophysiology for further analysis. These highly stringent parameters identified 9 genes
(Table 3) the levels of which were analyzed in clones of QGY-7703 cells expressing either
control shRNA or SND1 shRNA (QGY-shCon and QGY-shSND1-2), and control and SND1overexpressing clones of Hep3B cells (Hep3B-Con and Hep3B-SND1-17) by reverse
transcriptase PCR. AGRN, BCAM, CELSR2 and PNPLA7 mRNA expression was not affected
by changes in SND1 levels (Figure 1C). KCNJ and COL4A2 mRNAs were detected only in
QGY-7703 clones without showing any difference. PCSK9 mRNA levels were increased both
upon SND1 knockdown and overexpression making the observation difficult to interpret (Figure
1C). LAMB3 and PTPN23 mRNAs were increased upon SND1 knockdown and decreased upon
SND1 overexpression indicating a potential direct regulation by SND1 (Figure 1C).
PTPN23 has been identified as a tumor suppressor phosphatase inhibiting activation of
oncogenic Src and FAK (99,103,104). A role of PTPN23 in human HCC has not been studied
yet. Immunohistochemical analysis in HCC tissue microarray revealed PTPN23 expression in
normal adjacent liver with gradual decrease in staining with the stages of HCC (Figure 1D).
PTPN23 protein levels were lower in multiple human HCC cells compared to primary human
hepatocytes and h-TERT immortalized human hepatocytes (Hc3716-hTERT) (Figure 1E).
Immunofluorescence analysis identified PTPN23 in the cytoplasm of primary human hepatocytes
and at the same laser exposure PTPN23 was almost undetectable in QGY-7703 human HCC
cells (Figure 1F). PTPN23 protein and mRNA levels were significantly higher in multiple SND1
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knockdown clones of QGY-7703 cells versus control clone (Figure 1G and 1H). PTPN23 protein
levels were markedly lower in SND1 overexpressing clone of Hep3B cells as well as in the livers
of a transgenic mouse with hepatocyte-specific overexpression of SND1 (Alb/SND1) compared
to the respective controls (Figure 1G). These studies suggest that SND1 might directly regulate
PTPN23 levels.
SND1 binds to and degrades PTPN23 mRNA
We observed an inverse correlation between SND1 and PTPN23 levels and hypothesized that as
a nuclease SND1 might bind to and degrade PTPN23 mRNA. We treated human HCC cell lines
QGY-7703, HepG3 and HuH-7 with staphylococcal nuclease inhibitor pdTp that resulted in
upregulation of PTPN23 mRNA and protein (Figure 2A-B). In our previous study we established
subcutaneous xenografts of QGY-7703 cells in nude mice and treated the mice with pdTp which
significantly inhibited tumor growth (94). Analysis of these tumors showed upregulation of
PTPN23 protein and mRNA in pdTp treated group compared to untreated (Figure 2C-D). These
findings indicate that nuclease activity of SND1 is required to modulate PTPN23 levels.
To check direct binding and degradation of PTPN23 mRNA by SND1 we first performed RNA
gel shift assay using in vitro translated SND1 protein and
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P-labeled in vitro transcribed full-

length PTPN23 mRNA. SND1 protein, but not non-specific control protein, caused a mobility
shift of PTPN23 band over a period of 30-60 min only at 37°C but not at 4°C (Figure 2E). We
repeated the assay using only the 3’-UTR of PTPN23 as probe which also showed a mobility
shift upon incubation with SND1 protein indicating that SND1 binds to the 3’-UTR of PTPN23
mRNA (Figure 2F). To confirm that SND1 protein-PTPN23 mRNA interaction results in
degradation of the PTPN23 mRNA, we performed an in vitro RNA degradation assay in which
in vitro translated SND1 protein was incubated with total RNA from QGY-7703 cells at 37°C for
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15 minutes to 2 hours followed by purification of RNA and analysis of relative abundance of
specific RNA by Taqman Q-RT-PCR. In addition to PTPN23 we chose BCAM as a negative
control and LAMB3 as a positive control. Congruent to our initial observation incubation with
SND1 protein did not alter the levels of BCAM mRNA but there was a significant decrease in
the levels of LAMB3 and PTPN23 mRNAs, the effect on PTPN23 mRNA being more
pronounced that that on LAMB3 mRNA (Figure 2G). No significant change was noted in
LAMB3 or PTPN23 mRNA levels in the presence of a non-specific protein (Figure 2G).
PTPN23 overexpression reduces proliferation and dampens pro-oncogenic signaling in
HCC cells
To evaluate the effect of PTPN23 overexpression on human HCC cells, we established
tetracycline-inducible PTPN23-overexpressing clones in QGY-7703 and HepG3 cells.
Tetracycline dependent increase in PTPN23 protein levels was confirmed in QGY-Rep-Pt5 and
QGY-Rep-Pt6 and HepG3-Rep-Pt4 and HepG3-Rep-Pt8 clones (Figure 3A). Colony formation
assay showed significant inhibition in proliferation of these clones upon tetracycline treatment
(Figure 3B). Since PTPN23 functions as a phosphatase, we used lysates from untreated and
tetracycline-treated QGY-Rep-Pt5 and QGY-Rep-Pt6 cells to probe a receptor tyrosine kinase
array which identified inhibition of activation of several key kinases that were validated by
Western blot analysis (Figure 3C). Tetracycline treatment resulted in a decrease in
phosphorylated EGFR, c-Met, ERK and Src, without a change in total levels, in both QGY-7703
and HepG3 inducible PTPN23-overexpressing clones (Figure 3C). All of these oncogenic
kinases are key regulators of cell proliferation thereby indicating their involvement in mediating
PTPN23-dependent inhibition of proliferation. It should be noted that tetracycline treatment did
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not affect proliferation and activation of the aforementioned kinases in parental HepG3 and
QGY-7703 cells (Figure 6A-B) indicating that the observations are specific for PTPN23.
PTPN23 overexpression inhibits migration, invasion and EMT in HCC cells
c-Met and Src play a significant role in regulating migration and invasion of cancer cells.
Additionally in our initial kinase array we also identified phosphorylation of Focal adhesion
kinase (FAK), a key regulator of cellular adhesion and motility, to be downregulated upon
PTPN23 overexpression. Migration, determined by wound healing assay, and invasion,
determined by Matrigel invasion assay, showed significant inhibition upon tetracycline treatment
of both QGY-7703 and HepG3 clones demonstrating a role of PTPN23 in regulating these
processes (Figure 4A-B). These changes were associated with disorganization of actin
cytoskeleton network (Figure 4C) and inhibition in activation of FAK and β-catenin (Figure 4D).
Changes in cell motility are preceded by EMT (106). Indeed, upon tetracycline treatment a
pronounced inhibition in Snail and Slug, transcription factors regulating EMT, and N-cadherin
and vimentin, markers for EMT, was observed in both QGY-7703 and HepG3 PTPN23
overexpressing clones (Figure 4D). No difference was noted in migration and EMT marker
expression in tetracycline-treated parental HepG3 or QGY-7703 cells in comparison to untreated
cells (Figure 6C).
Collectively these findings indicate that PTPN23 inhibits multiple kinases in human HCC cells
resulting in abrogation of major hallmarks of cancer, such as proliferation, migration and
invasion.
PTPN23 inhibits in vivo growth of human HCC cells
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To confirm that in vitro phenotypes upon PTPN23 overexpression are retained in vivo we
established subcutaneous xenografts of inducible PTPN23-overexpressing clones of QGY-7703
cells that were fed either regular chow or doxycycline-containing diet. Over a period of 4 weeks
a significant inhibition in tumor growth was observed in doxycycline-fed mice compared to mice
fed regular chow (Figure 5A-D). Doxycycline treatment did not affect growth of parental QGY7703 cells (Figure 5C-D). Doxycycline treatment resulted in an increase in PTPN23 expression
in the tumor tissue which was associated with decrease in the proliferation marker PCNA and an
increase in the apoptosis marker cleaved caspase 3 (Figure 5E). Upon doxycycline treatment, a
pronounced inhibition in phosphorylation of EGFR, c-Met, Src, FAK and ERK was observed in
the tumor tissue compared to regular chow.
Discussion
Although SND1 has been implicated to function as a co-activator for transcription factors
(10,107), localization of SND1 protein almost exclusively in the cytoplasm of HCC cells (14)
indicate that post-transcriptional gene regulation is a major mechanism by which the nuclease
SND1 exerts its function. Of interest, along with its nuclease function SND1 has also evolved to
bind to specific mRNAs and increase mRNA stability (9). However, the factors that determine
whether SND1 binds to specific RNAs to degrade it or stabilize it remain to be identified. Since,
tudor domains are known to interact with oligonucleotides, a unique identifier sequence tag in
mRNAs might function as a message for SND1. Within the cytoplasm, SND1 can be part of
subcellular compartments such as ER membrane or spliceosome assembly, which are actively
involved in post-transcriptional gene regulation events. Site of SND1-mRNA interaction within
such compartments could also determine the effect of SND1 protein on target mRNA transcripts.
We hypothesized that identification of SND1 RNA interactome coupled with expression analysis
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will provide comprehensive insight into post-transcriptional gene regulation by SND1. We
identified 282 mRNAs that were specifically and significantly enriched in SND1 IP compared to
control IP. Additionally a large number of RNAs were found to be enriched in control IP
indicating that this assay tends to generate false positives and negatives. As such in our further
analysis we used extremely stringent parameters of very highly significant p-value with at least
10-fold enrichment in SND1 IP. This approach identified 9 transcripts. Further analysis of these
9 transcripts showed that only two, PTPN23 and LAMB3, displayed meaningful and reciprocal
changes with SND1 levels. Specificity of this interaction might be increased by UV-crosslinking
of RNA and protein prior to immunoprecipitation, thereby reducing false positives. Among the 9
genes studied we did not identify one that showed a positive correlation with SND1 suggesting a
potential regulation of mRNA stability by SND1. More in-depth analysis of the data with
comparison of global expression data is required to obtain comprehensive insight into the SND1
RNA interactome, which is currently in progress.
Nevertheless, our studies have unraveled a novel oncogenic mechanism of SND1 in driving
hepatocarcinogenesis. We show that SND1 specifically inhibits expression of PTPN23, a tumor
suppressor gene, by degrading its mRNA transcript. Previous studies documented Src and FAK
kinases as targets of the phosphatase PTPN23 (103,104). Our analysis of inducible PTPN23overexpressing clones reveal that in addition to Src and FAK, PTPN23 overexpression results in
inactivation of EGFR, c-Met, ERK and β-catenin. Whether PTPN23 actively dephosphorylates
all these kinases remains to be determined. The effect on ERK could be indirect since it is
downstream of EGFR. Similarly, the effect on β-catenin can also be indirect since it is
downstream of c-Met and FAK (108-110). c-Met activation is also initiated by integrin-mediated
activation of Src and FAK (110,111). Thus it might be possible that PTPN23 might directly
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dephosphorylate key upstream kinases resulting in inactivation of downstream kinase cascade
generating profound changes in proliferation, cell motility and disorganization of actin
cytoskeleton. A study illustrates interaction between PTPN23 and SH2/SH3 domain containing
proteins Grb2 and GrpL (112). This interaction might facilitate interaction between PTPN23 and
receptors such as EGFR and c-Met, as well as FAK.
Studies have shown that FGF-mediated induction in Src kinase activity phosphorylates and
inhibits PTPN23 phosphatase activity (103,113). Src is also known to be autophosphorylated
when under an active protein conformation state. Thus, a decrease in Src activation when
PTPN23 protein is overexpressed indicates a positive feedback loop wherein PTPN23 is capable
of maintaining its activity by inhibiting an active conformation state of Src.
A role of PTPN23 in the ESCRT complex has been identified, where it regulates trafficking and
lysosomal degradation of EGFR and PDGFR (100-102). We observed pronounced inhibition in
EGFR phosphorylation upon induction of PTPN23 expression. However, no change was
observed in the levels of total EGFR. These observations argue that in HCC cells PTPN23
functions predominantly as a phosphatase rather than regulating turnover of EGFR protein.
HCC is a highly virulent disease with no effective treatment for advanced disease (52). The only
FDA approved therapeutics, sorafenib and regorafenib, are multi-kinase inhibitors that provide
survival benefit of less than 3 months (114,115). The observation that PTPN23 has the ability to
inhibit multiple kinases that are known to play key roles in promoting HCC suggests that
PTPN23 overexpression might be a potential way to counteract HCC, which is supported by the
observation that doxycycline-mediated induction of PTPN23 resulted in significant inhibition of
HCC xenografts in NSG mice. HCC develops on a cirrhotic liver resulting from viral hepatitis
and alcoholic- or non-alcoholic steatohepatitis (52). Compromised liver function in HCC patients
69

renders small molecule inhibitors either relatively ineffective or toxic because of improper
metabolism. As such gene-based therapies might have lasting impact on the HCC disease
process. Nanoparticle or virus-based therapies are showing promise in clinical trials in HCC
patients (116,117) and might be used as vehicle for delivering PTPN23 in HCC patients.
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Figure 1. RNA immunoprecipitation sequencing (RIP-Seq) identifies PTPN23 as an SND1
interacting mRNA. (A) Schematic representation of RIP-Seq protocol. (B) Heat map shows
clustering of genes identified in SND1-IP. S: SND1 antibody; C: control IgG. (C) RT-PCR was
performed for the indicated genes in the indicated clones. The PCR products were separated on
1% agarose gel. GAPDH was used as control. (D) Immunohistochemistry for PTPN23 in normal
adjacent liver and different stages of HCC. Magnification: 100X. (E) Western blot for PTPN23
in the indicated cells. GAPDH was used as loading control. (F) Immunofluorescence for
PTPN23 in the indicated cells. (G) Western blot for PTPN23 and SND1 in the indicated clones
as well as in the livers of WT and Alb/AEG-1 mice. GAPDH was used as loading control. (H)
Analysis of PTPN23 mRNA levels by Taqman Q-RT-PCR in the indicated clones. GAPDH was
used for normalization. Data represent mean ± SEM. *: p<0.01.
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Figure 2. SND1 degrades PTPN23 mRNA. (A-B) The indicated cells were treated with 200μM
pdTp for 24 hours. PTPN23 mRNA levels (A) and protein levels (B) were measured by Taqman
Q-RT-PCR and Western blot, respectively. GAPDH was used for normalization and as loading
control. (C) FFPE sections from QGY-7703 xenografts, treated or not with 0.8mg/kg pdTp, were
stained for PTPN23. Magnification: 100X. (D) Analysis of PTPN23 mRNA levels by Taqman
Q-RT-PCR in QGY-7703 xenografts treated or not with the indicated doses of pdTp. GAPDH
was used for normalization. (E) RNA gel shift assay using radioactive full-length PTPN23
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mRNA as probe and in vitro translated control protein (MMP9) and SND1 protein at 37°C and
4°C for 30 and 60 min. (F) RNA gel shift assay using radioactive PTPN23 3’-UTR as probe and
in vitro translated SND1 protein at 37°C for 30 min. (G) In vitro translated SND1 or control
protein (MGLL) was incubated with 10μg total RNA from QGY-7703 cells at 37°C for the
indicated times. RNA was purified and Taqman-Q-RT-PCR was performed for the indicated
genes. GAPDH was used for normalization. For graphs, Data represent mean ± SEM. *: p<0.01
vs control.
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Figure 3. PTPN23 overexpression reduces proliferation and dampens pro-oncogenic
signaling in human HCC cells. (A) PTPN23-overexpressing inducible clones were treated with
4μg/ml of tetracycline for 24 hours and PTPN23 levels were analyzed by Western Blot. GAPDH
was used as loading control. (B) Colony formation assay using the indicated clones for 2 weeks.
Data represent mean ± SEM. *: p<0.01 vs untreated. (C) The indicated clones were treated with
4μg/ml of tetracycline for 48 hours and Western blot was performed for the indicated proteins.
GAPDH was used as loading control.
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Figure. 4. PTPN23 overexpression inhibits migration, invasion and EMT in HCC cells.
PTPN23-overexpressing inducible clones were treated or not with 4μg/ml of tetracycline and
migration by wound healing assay (A) and invasion by Matrigel invasion assay (B) were
performed as described in Experimental Procedures. Data represent mean ± SEM. *: p<0.01 vs
untreated. (C). The indicated clones were treated or not with 4μg/ml of tetracycline for 48 hours,
and actin cytoskeleton was stained. Magnification: 1000X. (D) The indicated clones were treated
with 4μg/ml of tetracycline for 48 hours and Western blot was performed for the indicated
proteins. GAPDH was used as loading control.
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Figure 5. PTPN23 induction inhibits in vivo growth of human HCC cells. Subcutaneous
xenografts from parental QGY-7703 and QGY-Rep-Pt5 and QGY-Rep-Pt6 clones were
established in male NSG mice which were fed regular chow or doxycycline-containing chow for
4 weeks. (A-B) Representative twice weekly measurement of tumor volume in QGY-Rep-Pt5
(n=3, A) and QGY-Rep-Pt6 (n=4, B) clones. Each circle represents one mouse. (C-D) Tumor
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volume (C) and tumor weight (D) at the end of the study. Data represent mean ± SEM. *: p<0.05
vs untreated. E. FFPE sections from the tumors of the indicated groups were immunostained for
PTPN23, PCNA and cleaved Caspase 3. F. Western blot for the indicated proteins in the tumors
of the indicated groups at the end of the study. GAPDH was used as loading control.
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Figure 6. Tetracycline does not affect proliferation, growth receptor signaling and
migration of HCC cells. Parental HepG3 and QGY7703 cells were treated with 4μg/ml of
tetracycline. (A) Colony formation assay was performed for 2 weeks and colonies were stained
with 0.1% Giemsa stain for 10 minutes at room temperature. (B) HepG3 and QGY cells were
treated or not with 4μg/ml of tetracycline for 48 hours and Western blot was performed for the
indicated proteins. GAPDH was used as loading control. (C) HepG3 and QGY cells were treated
or not with 4μg/ml of tetracycline and migration was observed by wound healing assay.
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SND1 overexpression in hepatocytes promote Nonalcoholic steatohepatitis (NASH)
Introduction
Hepatocellular carcinoma, in most cases, is diagnosed over a pre-existing primary pathology
(52). Approximately 80% of HCC cases are diagnosed in patients with a cirrhotic liver. Although
viral hepatitis has been historically the major risk factor predisposing individuals to risk of
developing HCC, in recent decades, occurrence of non-alcoholic fatty liver disease (NAFLD) as
a primary liver pathology causing HCC has been on the rise.
Pathologically, NAFLD is marked by accumulation of lipid in hepatic tissue in the absence of
alcohol abuse or other liver co-morbidities. NAFLD is characterized by initial accumulation of
triglycerides (TG) in hepatocytes (hepatic steatosis) with subsequent nonalcoholic steatohepatitis
(NASH). Globally, approximately 25% prevalence rate of NAFLD is present in human
population as indicated by a meta-analysis study (118). Age-wise stratification within this
population shows that majority of NAFLD presenting patients belong to age group of 40 – 60
years (118). Increasing incidence of obesity across western population has significantly increased
occurrence of NAFLD in past decade. About 60% of NAFLD patients were diagnosed with nonalcoholic steatohepatitis (NASH) within North America patient population (118). NASH,
presenting an inherent proinflammatory phenotype, increases the risk of HCC development in
patients. Fingas et. al. reviewed independent studies that interrogate occurrence of NASH as a
primary pathology in HCC patient population (119). Three independent studies show that 1013% of HCC patient population within the United States, present NASH as a primary pathology
(119).
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At a molecular level, NAFLD is marked by deregulation in lipid synthesis, lipid transport across
liver-gut axis and β-oxidation of fatty acids such that promotes steatosis. Pathological hallmarks
of NASH are oxidative stress, inflammation and fibrosis. Molecular basis of progression from
NAFLD to NASH is unclear and studies are being undertaken to better understand this
pathological transition.
A few studies describe a potential role of SND1 in regulating lipid metabolism. Keenan et.al.
identified SND1 in association with lipid droplets formed in lactating mammary glands and
adipocytes (120). This study established that this association was specific to lipid droplets and
was lost upon maturation and secretion of milk droplets (33). Co-fractionation and colocalization study in rat hepatocytes illustrates that rat homologue of SND1 protein associated
with lipid droplets in partial hepatectomy induced steatosis (121). Ectopic expression of SND1 in
rat hepatocytes increased lipid droplet formation whereas knockdown of endogenous SND1
protein decreased lipid droplet formation (122). Further, SND1 was detected as an endoplasmic
reticulum interacting protein in bovine liver lysate. Rat homologue of SND1 was also confirmed
to localize with ER and Golgi bodies within hepatocyte cytoplasm (33). Ectopic expression of
SND1 in rat hepatocytes increases secretion of phospholipid rich lipoproteins without altering
total composition of secretory phospholipids (123).
A more recent study illustrated that SND1 functions as a transcriptional co-activator of PPARγ in
pre-adipocytes and facilitates adipogenesis (122). This study demonstrated co-localization and
interaction of SND1 with PPARγ in preadipocytes (122). This interaction is essential for
maturation of adipocytes from pre-adipocytes (122). Ectopic expression of SND1 in presence of
PPARγ induced PPRE activity (122). Conversely, loss of endogenous SND1 protein results in
loss of expression of PPARγ target gene FABP2, but increases recruitment of histone
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deacetylases 1 and 3 in PPARγ transcription complex (122). This study also identified
CCAAT/enhancer binding protein as a novel transcriptional regulator of SND1 (122).
SND1 also regulates gene expression during TNFα-mediated inflammatory response in HCC
(92). Unique set of genes involved in glycerophospholipid metabolism is identified as
downstream target of transcriptional co-activator SND1 in TNFα-induced HCC cells (92). Loss
of function validation studies shows that SND1 is crucial for TNFα-mediated induction in
expression of these targets (92). This study concludes that transcriptional regulation by SND1 is
crucial for manifesting TNFα-induced changes in glycerophospholipid metabolism in HCC (92).
Furthermore, ectopic expression of SND1 in human hepatoma cells manifest significant increase
in cholesteryl ester (CE) level with a concurrent increase in cholesterol synthesis (124).
Upregulation in de novo cholesterol synthesis in SND1 overexpressing hepatocytes is
emphasized by an increase in expression of rate limiting enzymes of cholesterol synthesis such
as HMGCR (124).
Based on these studies, a potential role of SND1 in regulating NASH is hypothesized.
Alb/SND1, hepatocyte-specific transgenic mouse of human SND1, has been instrumental in
characterization of SND1 as a bona fide oncogene in HCC. Therefore, in this study, we aimed to
interrogate the role of SND1 in NASH and progression of NASH to HCC using mouse models.
Our findings suggest that genomic overexpression of SND1 increases age dependent steatosis,
chiefly due to increase in lipogenesis. Our prior study has demonstrated that SND1
overexpression in hepatocytes upregulates pro-inflammatory cytokines such as TNFα in an agedependent manner (94). SND1-induced steatosis and pro-inflammatory environment progresses
to NASH when animals are fed high fat diet (HFD). Prolonged feeding of HFD results in NASH
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induced HCC, which was more pronounced in Alb/SND1 mice. This study presents SND1 as a
mediator between metabolic stress and inflammation in hepatocytes. We aim to pursue future
studies in characterizing SND1 as a potential molecular target in NASH,
Materials and Methods
Diet induced fatty liver disease and steatohepatitis in mice
Floxed SND1 mice (SND1fl/fl) in C57BL/6 background was crossed with Alb/Cre (Jackson
laboratories) mice to generate SND1ΔHEP mice. Mice were fed regular chow and bred under
aseptic conditions. Generation and characterization of Alb/SND1 transgenic mouse in B6CBAF1
background was described in Chapter 2. Alb/SND1 mice were fed a high fat and cholesterol
containing diet (HFD, Harlan; TD. 88137) for a period of one year. This diet contains 0.2% total
cholesterol and 21% total fat by weight which provides 42% kcal (4.5 kcal/gm). All animal
studies were approved by the Institutional Animal Care and Use Committee at Virginia
Commonwealth University.
Patient Samples
Liver biopsy samples were collected from normal livers (biopsied for ruling out differential
diagnosis; n = 32) and NASH patients (n = 21). Stage 1 and 2 NASH patients according to
NASH CRN modified Brunt methodology were selected and patients with bridging fibrosis or
cirrhosis were excluded. The Institutional Review Board (IRB) of New York Methodist Hospital
approved these studies.
Lipid Profile study
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Serum liver enzymes were analyzed in the Molecular Diagnostic Laboratory, Department of
Pathology, VCU using standard procedures. Mouse Metabolic Phenotyping Center (MMPC),
University of Cincinnati analyzed plasma lipid and hepatic lipid profiles.
Picrosirius Red staining
Direct Red 80 was obtained from Sigma-Aldrich and a 0.1% solution was made in saturated
aqueous solution of picric acid (1.3% in water). FFPE sections were stained with picrosirius red
for 1 h and images were taken by a light microscope.
Immunohistochemistry and Western Blot
Immunohistochemistry was performed using formalin-fixed paraffin-embedded (FFPE) sections
as described in Chapter 2. The primary antibodies used was rabbit polyclonal SND1 antibody
(1:200, Sigma Aldrich). The signals were developed by avidin-biotin peroxidase complexes with
a DAB substrate solution (Vector laboratories). Images were analyzed using an Olympus
microscope.
Protein lysates were prepared by lysing cells in 1.5% n-dodecyl -D-maltoside (DDM) buffer
supplemented with protease and phosphatase inhibitor cocktail (Pierce). Lysates from liver tissue
were prepared by mechanical homogenization using the same buffer. Western blot was
performed as described in Chapter 2. Primary antibodies used were GAPDH (mouse
monoclonal; 1:1000; Santa Cruz) and FASN (rabbit polyclonal; 1:1000; Cell Signaling).
RNA purification, cDNA synthesis and quantitative real-time PCR
Total RNA was extracted using QIAGEN miRNAeasy Kit (QIAGEN). cDNA preparation was
done using ABI cDNA synthesis kit. Real-time polymerase 5 chain reaction (RT-PCR) was
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performed using an ABI ViiA7 fast real-time PCR system and Taqman gene expression assays
according to the manufacturer’s protocol.
Results
Alb/SND1 mice manifest NAFLD phenotype and HFD-induced NASH and HCC
In Alb/SND1 mice, SND1 overexpression in hepatocytes results in a pro-inflammatory hepatic
microenvironment with constitutive activation of NF-κB and increased Kupffer cell population that lead
to spontaneous HCC development at one year of age (94). At this age, Alb/SND1 mice also showed

marked steatosis compared to WT littermates as revealed by histological analysis (Figure 1A).
Liver weight from one year old Alb/SND1 mice is significantly higher than wildtype littermates
(Figure 1B). Serum AST and ALT levels were significantly higher in one year old Alb/SND1
mice (Figure 1C). NASH is marked by fibrosis and inflammation. We demonstrated an increase
in inflammatory cytokines IL-6 and TNFα in one year old Alb/SND1 livers versus WT livers
(Chapter 2, Figure 2G) (94). We, therefore, checked for fibrosis, in these livers. Picrosirius Red
staining of FFPE liver sections showed significant fibrosis in one year old Alb/SND1 mice
compared to WT (Figure 1A).
We next checked whether feeding HFD propagates NASH to HCC in Alb/SND1 mice. With
HFD feeding for one year, Alb/SND1 mice showed an increase in liver size with corresponding
increase in the magnitude of steatosis compared to WT (Figure 2A-B). HFD feeding for one year
induced tumor formation in the liver both in WT and Alb/SND1 mice. However, the tumorigenic
response was more robust in Alb/SND1 mice (Table 5 and Figure 2B). Concurrently, liver
weight of HFD-fed Alb/SND1 cohort was significantly higher than that of HFD-fed WT cohort
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(Figure 2C). Serum levels of liver function enzymes, AST, ALT and AP, were significantly
elevated in HFD-fed Alb/SND1 mice compared to corresponding WT mice (Figure 2D).
Serum lipid profile analysis revealed increased triglyceride (TG) and phospholipid (PL) levels in
chow-fed one year old Alb/SND1 mice compared to WT littermates (Figure 2E-F). Upon HFD
feeding, a significant increase in serum TG, PL and cholesterol levels were observed in
Alb/SND1 mice versus WT (Figure 2E-G). Hepatic TG and cholesterol levels were significantly
higher in chow-fed one year old naïve Alb/SND1 mice in comparison to WT (Figure 3A-B).
HFD feeding significantly increased hepatic TG in Alb/SND1 mice (Figure 3A), but no
difference was noted in cholesterol levels, compared to WT littermates (Figure 3B). Alb/SND1
mice manifested significantly higher hepatic LDL and VLDL levels, both upon feeding regular
chow or HFD, compared to WT littermates (Figures 3C-D), with both regular chow and HFD
feed (Figure 3C). HFD significantly increases VLDL and HDL levels in both wildtype and
transgenic mice. No significant difference is noted between wildtype and transgenic VLDL
levels (Figure 3D).
To summarize, SND1 overexpression increases both serum and hepatic triglyceride and hepatic
LDL levels with regular chow diet. Histologically, Alb/SND1 mice present increased steatosis
and fibrosis, indicating that SND1 endogenously regulates lipid metabolism. With HFD, NASH
progresses to a more pronounced HCC phenotype in Alb/SND1 livers with markedly higher
necrosis of hepatic tissue. Serum triglyceride and total cholesterol levels, hepatic triglyceride and
LDL levels are consistently upregulated in HFD fed Alb/SND1 mice. Therefore, we conclude
that SND1 overexpression causes NASH in later adulthood, which progresses into HCC with
HFD.
SND1 is overexpressed in human NASH
86

We evaluated SND1 expression levels in the livers of NASH patients by immunohistochemistry.
We observe a significant increase in SND1 protein expression in livers of NASH patients
compared to non-NASH individuals (Figure 4A). Asghourpur et. al. reported a novel diet
induced murine model (DIAMOND) of NASH-HCC in which mice were fed high fat and high
sucrose diet for one year (125). A significant upregulation of SND1 was observed in the livers of
both NASH and NASH- HCC compared to chow-fed controls (Figure 4B). Collectively these
findings indicate a regulatory role of SND1 from progression of NASH to NASH-HCC.
SND1ΔHEP mice are protected from high fat diet induced steatosis
To further confirm our observation, we created a hepatocyte specific SND1 knockout mouse
(SND1ΔHEP) and monitored these mice for one year. Genetic deletion of SND1 in hepatocytes
was associated with a pronounced reduction in age-dependent steatosis compared to SND1fl/fl
mice (Figure 5A). At one year of age, liver weight was significantly lower in SND1 ΔHEP mice
compared to SND1fl/fl littermates (Figure 5B). Hepatic TG, but not cholesterol, showed a
significant decrease in one year old SND1ΔHEP mice versus SND1fl/fl littermates (Figure 5C-D).
SND1 regulates expression of lipogenic, lipolytic and lipid transport marker genes
To obtain insight into the mechanism by which SND1 regulates steatosis, we check expression
profile of genes regulating lipid metabolism. Regular chow fed Alb/SND1 livers show a
significant upregulation in FASN protein level, compared to WT littermate (Figure 6A). A
significant downregulation of Fatty acid Binding protein 1 (Fabp1), Scd1, Scd2 and Srebf1 in
SND1ΔHEP livers was observed compared to SND1fl/fl littermates Thus, our results indicate that
SND1 overexpression might upregulate de novo lipogenesis in liver (Figure 6D).
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Conversely, SND1ΔHEP livers showed a significant increase in expression of rate-limiting genes
regulating β-oxidation of fatty acids, such as Cpt1A and Acox1 (Figure 6C). No significant
difference is noted in expression of ACADM1 and ACAD1 (Figure 6C).
In SND1ΔHEP liver, a significant upregulation of lipid transport proteins, such as ABCA1,
ABCG1, ABCG5, ABCG8, Apolipoprotein E (ApoE) and Diacylglycerol transferase (DGAT),
was observed compared to SND1fl/fl littermates (Figure 6E). Hence, it might be inferred that
SND1 inhibits lipid export from liver, thereby increasing total hepatic lipid content.
Re-analysis of RIP-Seq data demonstrated association of several mRNAs regulating lipid
synthesis, metabolism and transport with SND1 protein (Table 6). As yet the fate of this
interaction on each mRNA is not known. However, in light of data presented in Figure 6, it
might be hypothesized that binding of SND1 with mRNAs regulating lipogenesis, such as
FASN, SREBF1 and SREBF2, might result in increased stability of these mRNAs or increased
translation. Further validation studies need to be performed on these mRNAs to establish
meaningful conclusion.
Discussion
This is a preliminary study demonstrating potential role of SND1 in regulating NASH and
NASH-HCC. We demonstrate development of spontaneous NASH in Alb/SND1 mice which
further progresses into HCC upon feeding HFD. This finding is corroborated in human NASH
patients as well as in DIAMOND model of NASH-HCC. Conversely, we demonstrate marked
resistance of development of NASH in SND1ΔHEP mice. Gene expression analysis suggests that
SND1 increases de novo lipogenesis, and decreases β-oxidation of fatty acids and transport of
lipids from the liver. These mechanisms collectively might increase TG accumulation in the liver
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resulting in steatosis. Our previous observations that SND1 activates NF-κB signaling and
increases inflammation and functions as a driver oncogene provide additional mechanism of
development of NASH and NASH-HCC.
The mechanism by which SND1 is overexpressed in NASH patients remains to be determined.
However, SND1 expression is increased by inflammatory cytokines and SND1 promoter carries
binding site for NF-κB (31). HFD-induced inflammation might induce SND1 which can further
exacerbates the scenario by increasing the hallmarks of NASH thereby creating a vicious cycle
of positive feedback culminating into HCC. Further studies using luciferase promoter based
assays with chemical inhibitors of and NF-κB might shed light on the mechanism of SND1
overexpression in NASH.
SND1 has been identified as a co-activator for PPARγ. In the liver PPAR family of transcription
factors are primarily involved in positively regulating genes in the fatty acid β-oxidation
pathway. However, we observe an increase in Cpt1a and Acox1 in SND1ΔHEP livers which
argues against PPARγ-mediated events contributing to SND1-induced NASH. Additionally in
hepatocytes SND1 is almost exclusively detected in the cytoplasm suggesting that SND1regulated cytoplasmic events, rather than nuclear events, confer SND1-induced phenotypes.
SND1 can function as a RNase but it has also evolved to bind to specific mRNAs to increase
mRNA stability and translation. RIP-Seq data identifies association of SND1 with key mRNAs
regulating lipid metabolism. In this context, post-transcriptional regulation of these genes by
SND1 might be the major underlying mechanism of SND1-induced NASH, a hypothesis that
needs to be experimentally validated.
In addition to analyzing underlying molecular mechanism, we also need to feed HFD to
SND1ΔHEP mice to determine the level of resistance of these mice to NASH development. This is
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an important experiment, confirming SND1 as a potential target in NAFLD which lead to
evaluation of pharmacological or genetic inhibition of SND1 as a potential intervention strategy
in HFD-induced NASH. HFD-fed WT mice can be administered with described doses of pdTp
(Chapter 2). Nanoparticle mediated delivery of siRNAitargeting SND1 can be a potential high
efficacy approach as well.
However, an important observation is that SND1 protein expression increases with advancing
NAFLD and NASH in wildtype mice. Underlying mechanism that drives SND1 overexpression
remains to elucidated. PPARγ is an important transcription factor driving ligand dependent
transcription to regulate lipid metabolism (126). Upregulation of PPARγ activity in NAFLD,
under high hepatic triglyceride condition has been established (126,127). Studies have also
shown that SND1 functions as transcriptional coactivator with PPARγ in HCC (122). PPARγ
mediated upregulation in HFD fed mice can be a potential mechanism driving liver specific
SND1 overexpression in NAFLD presenting mice. SND1 expression might be regulated by a
positive feedback loop in co-operation with PPARγ. SND1 promoter also carries binding site for
NFκB (128). Thus, NFκB upregulation in NAFLD presenting livers can potentially upregulate
SND1 transcription. Luciferase promoter based assays with chemical inhibitors of PPARγ and
NFκB might shed light on role of these transcriptional factors in SND1 overexpression.
We have identified and characterized expression profile of marker genes regulating lipogenesis
and lipolysis in liver. RIPSeq data also corroborates that SND1 protein associates with
transcripts of specific rate limiting enzymes in lipid synthesis and metabolism. SND1 is known
to bind to mRNA molecule, increase its stability and upregulate mRNA translation. We have also
shown that SND1 can bind to specific mRNA molecule and degrade it. Thus, specific SND1
action on each of these genes remains to be deduced. It can be expected from prior research that
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SND1 protein stabilizes transcripts of lipogenic proteins such as SREBP1, SCD1, SCD2 and
FASN, and degrades transcripts of lipolytic proteins such as CYP1A and ACOX1.
Our findings show that genetic deletion of SND1 from hepatocytes significantly upregulates
expression of lipid transport channel proteins exporting lipids from liver – ABCA1, ABCG1,
ABCG5, ABCG8, ApoE and DGAT. Since these proteins are responsible for hepatic secretion of
lipids, it can be concluded that SND1 drives lipid accumulation within hepatocytes by decreases
expression of transport channel proteins. Decrease in channel activity must be quantified in
concurrence with downregulation of channel protein expression.
Although we have employed SND1ΔHEP model to analyze differential gene expression, we have
not observed effect of HFD on lipid metabolism in SND1ΔHEP mice. This is an important
experiment, confirming SND1 as a potential target in NAFLD. Finally, it is important to show
that targeting SND1 or chemical inhibition of SND1 via pdTp reverses the observed phenotype
and protects against NAFLD in vivo. HFD fed wildtype animals can be administered with
described doses of pdTp (Chapter 2). Nanoparticle mediated delivery of RNAi targeting SND1
can be a potential high efficacy approach for this experiment.
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Figure 1. Alb/SND1 mice manifest steatosis and fibrosis. H&E staining of FFPE liver sections
from one year old Alb/SND1 and wildtype mice was performed. 0.5% picrosirius stain was used
for staining FFPE liver sections from one year old Alb/SND1 and wildtype mice. Stained
sections were imaged at 100X and 400X maginifcation using Olympus light microscope. B.
Measurement of liver weight from one year old wildtype (WT) and Alb/SND1 (TG) mice (n =
9). Data represent mean ± SEM. *: p<0.05 vs wildtype. C. Serum levels of liver function
enzymes in one year old wildtype (n = 11) and Alb/SND1 (n = 17) mice. Data represent mean ±
SEM. *: p<0.05 vs wildtype or #: p<0.01 vs wildtype.
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Figure 2. HFD induced NASH and HCC in Alb/SND1 mice. Alb/SND1 and wildtype
littermates were fed HFD for one year. Liver was harvested, weighed and observed for
macroscopic nodules. A. Photographs of representative livers. B. H&E staining of FFPE liver
sections harvested form one year old HFD fed Alb/SND1 and wildtype mice. Images were
captured at 100X magnifcaition using Olympus light microscope. Measurement of liver weight
(C), and serum AST, ALT and total protein (D) (WT: n = 10; Alb/SND1: n = 12). E.
Measurement of serum triglyceride (RC: n = 8, HFD: n = 9). F. Measurement of serum
phospholipids (RC: n = 9, HFD: WT n = 8 / Alb/SND1 n = 11). G. Measurement of serum
cholesterol (RC: WT n = 9/ Alb/SND1, n = 7, HFD: n = 8). Data represent mean ± SEM. *:
p<0.05 vs wildtype RC or #: p<0.01 vs wildtype HFD.
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Figure 3. Hepatic lipid fractionation analysis in regular chow (RC) and HFD fed one year
wildtype and Alb/SND1 mice. A. Measurement of hepatic triglycerides (RC: n = 6, HFD: n =
5). Data represent mean ± SEM. *: p<0.05 vs wildtype RC or #: p<0.01 vs wildtype HFD. B.
Measurement of hepatic LDL (RC: WT, n = 6/ AlbSND1, n = 5, HFD: n = 5). Data represent
mean ± SEM. *: p<0.05 vs wildtype RC or #: p<0.05 vs wildtype HFD. D. Measurement of
hepatic VLDL (RC: n = 6, HFD: n = 5). Data represent mean ± SEM. *: p<0.05 vs wildtype RC.
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Figure 4. SND1 is overexpressed in NASH. A. IHC on FFPE liver sections harvested from
human NASH patients for biopsy, using anti- SND1. Images were captured at 100X
magnification using Olympus light microscope. B. IHC on FFPE liver sections harvested from
RC or HFD fed wildtpe mice using anti-SND1. Images were captured under 100X and 400X
magnification with Olympus light microscope.
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Figure 5. SND1ΔHEP mice are protected against steatosis. A. H&E staining of FFPE liver
sections from RC fed one year old SND1fl/fl and SND1ΔHEP. B. Measurement of liver weight from
one year old SND1fl/fl and SND1ΔHEP mice (n = 9). C. Measurement of hepatic triglyceride in RC
fed one year old SND1fl/fl and SND1ΔHEP mice (n = 9). ). D. Measurement of hepatic cholesterol
in RC fed one year old SND1fl/fl and SND1ΔHEP mice (n = 6). Data represent mean ± SEM. *:
p<0.05 vs SND1fl/fl.
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Figure 6. SND1 regulates denovo lipogenesis and β-oxidation of fatty acids. Western blot
analysis of total protein from Alb/SND1 and WT liver was performed to check SND1 and FASN
protein expression. B. Measurement of serum non-essential fatty acids (NEFA) in Alb/SND1 and
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wildtype littermates (n = 9). Real-time quantitative PCR was performed using cDNA library
synthesized from total mRNA lysate of one year old SND1fl/fl and SND1ΔHEP livers. Expression
of genes regulating mitochondrial β-oxidation of fatty acids (C) and denovo lipogenesis (D) was
analyzed. Data represent mean ± SEM. *: p<0.05 vs SND1fl/fl.

98

Discussion
SND1 is a multifunctional protein, identified and characterized as an oncoprotein in multiple
cancers

–

colorectal,

prostate,

breast,

glioblastoma

and

hepatocellular

carcinoma

(14,16,21,71,129). Recent studies have identified SND1-BRAF fusion products in pancreatic and
lung cancers (130,131). Mechanistic studies have been performed to deduce molecular
mechanisms employed by SND1 to promote carcinogenesis in aforementioned cancers. It is
established that SND1 employs unique and diverse mechanisms, at transcriptional and posttranscriptional level, to affect multiple hallmarks of cancer (73). SND1 exerts its pro-oncogenic
function primarily by regulating gene expression – as a transcriptional co-activator (35,122),
RNase (14) and RNA binding protein (9). SND1 is also a functional component of spliceosome
assembly, promoting alternative splicing of oncogenic splice variants (47). SND1 has been
identified in stress granules, regulating ER stress response (49), which affects major
transcriptional programs under cellular stress. Thus, it can be concluded that SND1 globally
regulates gene expression within cancer cells. SND1 precisely manipulates transcriptome and
subsequently proteome to drive carcinogenesis. Specifically in hepatocytes, we find that SND1
profoundly impacts tyrosine kinase signaling network as well as hepatic lipid metabolism. We
unravel that hepatocyte specific overexpression of SND1 and subsequent transcriptomic change
causes a pro-tumorigenic shift in liver microenvironment.
Prior studies have validated SND1 as an oncogene in HCC, employing in vitro functional assays
with phenotypic endpoints such as proliferation, migration, invasion and angiogenesis
(14,18,19). We have also deduced specific signaling pathways regulated by SND1 to promote
HCC growth. SND1 functions as an RNase in RISC, upregulating oncogenic microRNAs that
target tumor suppressor genes such PTEN, SPRY2, TGFBR2 (14). SND1 can also upregulates

99

AT1R protein expression by binding to and increasing stability of AT1R mRNA (9).
Subsequently, it was elucidated that AT1R upregulation promotes TGFβ and ERK signaling,
thus promoting EMT, migration and invasion of HCC cells (18). SND1 also promotes NFκB
activation and signaling via miR221 regulation, to promote angiogenesis in HCC cells. (19)
Goals of this study were to characterize oncogenic function of SND1 in vivo and understand
SND1 mediated regulation of hepatocyte. Employing hepatocyte specific transgenic mouse
model, we illustrate that SND1 overexpression promotes inflammation, increases hepatic TIC
population and thereby drives oncogenesis in hepatocytes (94). An interesting observation of this
study is that SND1 overexpression allowed upregulation of specific pro-oncogenic and proinflammatory genes in an age specific manner. For example, we observe that c-Myc and TNFα
expression is upregulated at 2 months and further increased at 1 year (94). TNFα was
overexpressed congenitally and consistently with age (94). On the other hand, IL6 was observed
to be upregulated only in later adulthood in Alb/SND1 mice (94). This was our first insight into
unique transcriptomic changes driven by SND1 overexpression in liver. We also find that SND1
overexpression in hepatocytes results in constitutive activation of NFκB signaling and increased
Kupffer cell population in the liver (94). Consistent upregulation of TNFα is predicted to
promote NFκB activation, which might exaggerate TNFα expression with age. Pro-inflammatory
signaling can increase macrophage invasion of hepatic tissue, which in turn secrete proinflammatory cytokines. Persistent inflammation and increased secretion of cytokines can injure
hepatocytes, which secrete IL6.
IL6 secreted from hepatocyte activates hepatic stellate cells, a known signaling pathway to
initiate hepatocarcinogenesis (132). Activated stellate cells further influence the secretory
cytokine profile of liver in a pro-inflammatory manner and allow macrophage invasion in liver.
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Activated hepatic stellate cells can also senesce and cause senescence associates secretory
phenotype (SASP) (133,134). Macrophages are also shown to promote hepatic tumor initiating
cell population via IL-6/ Stat3 signaling (91). It is possible that SND1 overexpression mediates
changes in cytokine secretome of liver by activating stellate cells or Kupffer cells. We, thus,
extrapolate that SND1 overexpression initiates pro-oncogenic microenvironmental changes in
liver physiology, which culminate in HCC. However, our study does not demonstrate activation
status of stellate cells and its secretory profile. Studying effect of SND1 overexpression on other
hepatic cell types, especially hepatic stellate cells is critical to understand mechanism underlying
SND1 mediated microenvironmental changes in the liver.
This study illustrates that SND1 overexpression is associated with age-dependent increase in
hepatic TIC population, a novel pro-oncogenic function of SND1 in HCC (94). We observe this
increase in TIC population only in later adulthood, and no difference was noted between young
wildtype and Alb/SND1 liver TIC population. Thus, SND1 must drive specific molecular
signaling causing an increase in TIC population with age. Underlying mechanism responsible for
increased hepatic TIC population in Alb/SND1 model remains to be elucidated. Hepatocytes are
terminally differentiated cells in liver. It is known that hepatic TICs arise from de-differentiated
hepatocytes. Thus it can be expected that SND1 reprogrammes hepatocytes into a tumor
initiating phenotype. Specific transcriptome and proteome changes confirming this hypothesis
need to be investigated with detailed molecular approach.
We also observe an endogenous upregulation of AKT and ERK signaling in HCC bearing
Alb/SND1 livers (94). AKT/ ERK upregulation was consistent in one year old naïve Alb/SND1
livers and seen to promote hepatocyte transformation. AKT/ ERK upregulation was not observed
in young Alb/SND1 livers. This observation further strengthens our hypothesis that SND1
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overexpression alters the hepatic microenvironment such that pro-oncogenic events accumulate
with age and result in HCC.
Combining our observation from Alb/SND1 model with previous in vitro studies, we conclude
that SND1 manipulates hepatocyte transcriptome and proteome to allow transformation of
hepatocytes and promote HCC growth.
Post-transcriptional regulation of gene expression via RISC and direct mRNA-protein interaction
has already been validated in HCC (14,18). We aimed to further characterize regulatory function
of SND1 in HCC to better understand mechanism employed by SND1 protein to drive
hepatocarcinogenesis. Since, SND1 pre-dominantly localizes within the hepatocyte cytoplasm
(14), we focus on post-transcriptional regulatory mechanism employed by SND1. Using RIPSeq
approach, we identify 282 mRNA transcriptions in significant association with SND1 protein in
human HCC cells. In vitro analysis confirmed that SND1 uniquely regulated fate of each
interacting transcript. We established that RNase function of SND1 was specific to chosen
transcripts. For example, we observe that SND1 degrades PTPN23 and LAMB3 mRNA but does
not degrade BCAM mRNA. Fold-change and SND1-mRNA interaction significance was
approximately equal for above three transcripts in RIPSeq. This led us to hypothesize that SND1
uniquely chooses fate of interacting mRNA molecule. Mechanism employed by SND1 to
identify downstream fate of target transcript is unknown. Tudor domain of SND1 protein is
capable of interacting with oligonucleotides. It is possible that SND1 identifies specific sequence
in mRNA transcripts to decide between stabilization or degradation of target mRNA. Analysis of
mRNA sequences, especially in 3’UTR region of identified transcripts can provide crucial
insight. Independent studies have shown SND1 to be a functional component of multi-protein
complexes such as RISC (14), stress granules (49) and spliceosome assembly (46). In HCC, we
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observe that SND1 also localizes within ER membrane (data not published). Hence, location of
SND1-mRNA interaction could potentially predetermine fate of target mRNA. To study this
hypothesis, we need to demonstrate localization of SND1- mRNA interaction within HCC cells,
and validate SND1 function within specific subcellular compartments.
We used a singular identification, PTPN23, from RIPSeq data to demonstrate that SND1 protein
can bind and degrade specific mRNA transcripts. Importantly, downregulation of PTPN23
transcript affected multiple signaling pathways in HCC cells. Validation of c-Met and EGFR as
downstream signaling targets of PTPN23 in HCC is also a novel discovery of this study. We
conclude that PTPN23 targets EGFR, c-Met, Src, FAK, ERK and β-catenin signaling in human
HCC cells. Hence, by downregulating a single phosphatase, SND1 broadly impacts receptor
tyrosine kinase signaling in HCC. This finding emphasizes global impact of SND1-mediated
gene regulation on HCC proteome.
In this study we present two novel molecular therapeutic approaches in HCC management. pdTp
mediated chemical inhibition of SND1 significantly reduced HCC growth in orthotopic model
(94). We also deduce specific signaling events inhibited in pdTp treated HCC tumors. SND1
inhibition successfully decreases NFκB activation, proliferation and induces programmed cell
death (94). This is the first attempt to administer pdTp in vivo as a drug. We report this chemical
to be non-toxic in murine models. However, we need to ensue toxicity and pharmacokinetic
studies for learning pdTp metabolic rate and effect in higher mammalian models. Since PTPN23
overexpression restricts HCC growth, we present PTPN23 as a potential multi-kinase inhibitor
for HCC management. Virus based sophisticated approaches must be developed and tested to
validate PTPN23 mediated inhibition of kinase signaling and HCC growth in vivo.
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Apart from cancer, we partially characterize role of SND1 in NAFLD and NASH. Alb/SND1
mice present NAFLD phenotype in later adulthood. Histologically, Alb/SND1 livers present
greater steatosis than wildtype littermates. Serum and hepatic lipid profile analysis shows that
Alb/SND1 mice present higher triglyceride and cholesterol levels. SND1 overexpression also
accelerates HCC progression in HFD fed NASH presenting Alb/SND1 mice. Lipid profiles
worsened upon HFD feeding in Alb/SND1 mice. Progression of HFD induced NAFLD into
NASH and HCC can be attributed to upregulation of proinflammatory and pro-oncogenic
signaling by SND1. Although we conclude that SND1 overexpression associates with advancing
NAFLD/NASH and causes aggressive NASH induced HCC, we do not understand role of SND1
in lipid metabolism. It is crucial to deduce specific mechanisms employed by SND1 to
deregulate lipid metabolism manifest the observed phenotype. SND1 functions as a
transcriptional coactivator of PPARγ (122) and regulates expression of TNFα response genes
involved in cholesterol metabolism (92). There are multiple studies associating SND1 protein
with cellular lipid storage and homeostasis (33,123,124). However, there is a lack of mechanistic
understanding of SND1 mediated regulation of lipid synthesis, metabolism and storage.
Hepatocyte specific deletion of SND1 significantly affected expression of genes encoding
lipogenic, lipolytic enzymes as well as lipid transport channel proteins. SND1ΔHEP liver manifest
increased expression of genes promoting efflux of lipids from hepatocytes and decreased
expression of lipogenic enzymes. Specifically, we observe an induction in cholesterol export
channel protein ABCG5 and ABCG8 in SND1ΔHEP liver. Since literature supports association of
SND1 with lipid droplets in hepatocytes, it is possible that SND1 protein protects cholesteryl
esters within lipid droplets from enzymatic degradation. Expression of proteins regulating βoxidation of fatty acids was also increased in SND1ΔHEP mice. Overall, it is indicated that SND1
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might regulate enzymatic lipid mobilization within liver. Thus, SND1 protein alters hepatocyte
gene signature such that it promotes NAFLD phenotype.
A pivotal observation of our study is that SND1 expression increases with advancing NAFLD
pathology and NASH in wildtype mice. Deducing the mechanism driving SND1 upregulation is
important to understand role of SND1 in NAFLD to NASH progression. SND1 promoter region
has a NFκB binding site (128). Since NFκB is upregulated in steatotic livers, NFκB mediated
transcriptional upregulation of SND1 is a potential mechanism. In Alb/SND1 model, we observe
constitutive activation and upregulation of NFκB (94). A positive feedback loop between SND1
and NFκB proteins could potentially drive SND1 upregulation and inflammation of hepatic
tissue. Canonical transcription factors such as PPARα/γ and SREBP1c are known to play crucial
role in driving and maintaining NAFLD gene expression signature. Role of these proteins in
transcriptional upregulation of SND1 must be checked with luciferase assay based approach.
Overall, this research presents SND1 as a molecular target balancing metabolic stress,
inflammation and oncogenesis. We illustrate effect of SND1 overexpression in HCC and NASH
disease in an in vivo model. We also elucidate detailed molecular changes regulated by SND1 in
development and progression of SND1. This study also presents two novel functions of SND1 –
1) upregulation of hepatic TIC population 2) binding and degrading mRNA to downregulate
tumor suppressor in HCC. RIPSeq provides an insight into regulatory role of SND1 on
hepatocyte transcriptome. We affirm that SND1 drives disease specific transcriptome and
proteome changes within hepatocytes. SND1 knockout from hepatocytes was found to be viable
without any adverse effect on animal physiology. Importantly, we present SND1 inhibition and
molecular targeting as a viable high efficacy approach in HCC and NASH management.
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Table 1. No. of nodules in 1 year old Alb/SND1 mice

Nodules (mm)
ID

1-2

>3

>10

TG1

7

0

1

TG2

No nodule

TG3

No nodule

TG4

No nodule

TG5

3

0

TG6

No nodule

TG7

No nodule

TG8

No nodule

0

TG9

0

0

1

TG10

0

1

0

TG11

No nodule

TG12

No nodule

TG13

0

1

0

TG14

0

1

0
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Table 2. No. of nodules in DEN-treated mice

Nodules (mm)
ID

1-2

>5

>10

WT1

0

0

1

WT2

3

5

0

WT3

0

5

0

WT4

0

0

10

WT5

No nodule

WT6

No nodule

WT7

No nodule

WT8

No nodule

TG1

4

27

44

TG2

0

0

41

TG3

Entire liver

TG4

Entire liver

TG5

Entire liver

TG6

Entire liver

TG7

Entire liver

TG8

Entire liver

TG9

Entire liver

TG10

Entire liver
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Table 3. SND1 target genes identifications from RIPSeq data

Gene ID

Gene

Control
mean

SND1 IP
Fold
P- value
mean
Enrichment

AGRN

Agrin

695.054

8559.479

12.314

2.21E-31

BCAM

Basal Cell Adhesion molecule

84.99

1426.40

16.78

1.73E-65

2604.322

10.293

1.60E-69

CELSR2

Cadherin EGF LAG seven-pass G252.998
type Receptor 2

COL4A2

Collagen type IV alpha 2

211.599

2141.286

10.119

6.18E-38

KCNJ12

Potassium inwardly rectifying
channel, subfamily J, channel 12

5.0861

58.448

11.491

9.43E-14

LAMB3

Laminin beta 3

446.552

4520.898

10.124

1.30E-108

PCSK9

Proprotein Convertase Subtilisin/
kexin 9

2.13

34.94

16.39

1.14E-09

PNPLA7

Patatin like phospholipase domain
containing 7

2.274

24.514

10.777

1.17E-05

PTPN23

Protein Tyrosine Phosphatase non313.245
receptor type 23

3144.123

10.037

1.56E-114
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Table 4. Primers used for PCR amplification of cDNA of target genes
GENE

PRIMER

SEQUENCE 3’ – 5’

AGRN

Forward

CCACAAGAACGAGCTGATGCTCAAC

Reverse

GCACGGGCTCTTCTTGCAGACG

Forward

ATGCCCAGGCGGTGCGCTT

Reverse

CCACGCACACGTAGTCTCGCTCGT

Forward

TCTGTCCATCCTCAGCGTCGAAC

Reverse

CAGCTTGCAGGACTGGCATCTGA

Forward

GTGTGAAGAAGTTTGATGTGCCGTG

Reverse

GTTCCGTTGCAGCCATCGTAGC

Forward

CCTACAGCATCGTGTCATCGGAG

Reverse

CAGCGAGAAGATGAGCAGCATGTAC

Forward

CTTCATCTACCTGTGGACTGACCAA

Reverse

CTCCATCATGACTTCTTGAAGCTGG

Forward

GACTACATCGAGGAGGACTCCTCT

Reverse

ACACTTGCTGGCCTGTCTGTGGAA

Forward

CGTGAAGAATTCTCACCTGCCATC

Reverse

AGTGTCCTGGATGCAGACCTCCA

Forward

TTCACTTCCAGCCAGCTGTGAAGAA

Reverse

AGACTTGCCTGAGAAGATCTCTGTC

Forward

ATGTTCCAATATGATTCCACCCAT

Reverse

AGGCATTGCTGATGATCTTGAG

BCAM

CELSR2

COL4A2

KCNJ12

LAMB3

PCSK9

PNPLA7

PTPN23

GAPDH
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Table 5. No. of nodules in one year old HFD fed Alb/SND1 (TG) and wildtype (WT) mice

ID
TG 1
TG 2
TG 3
TG 4
TG 5
TG 6
TG 7
TG 8
TG 9
TG 10
TG 11
TG 12
TG 13
TG 14
TG 15
TG 16
WT 1
WT 2
WT 3
WT 4
WT 5
WT 6
WT 7
WT 8
WT 9
WT 10
WT 11
WT 12
WT 13

Nodules
>/= 5

1-2
4

>/=10
1 (20mm)
1 (20mm)

1
1

3
1
1

2
1
1
2

1 (20mm)
1
2
5

25
3

4
2

2
3
1

2

2
10
2
1
1
4

1
1
1 (20mm)
1

2
1
1
1

3
1
7
2
2

1
1
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1
1

Table 6. Genes involved in lipid metabolism from RIPSeq data
ProbeIDs

log2FoldChange

pval

adjp

ABCA2

2.64

2.40E-49

3.54E-47

ACACA

1.53

3.87E-28

1.88E-26

ACADVL

1.43

7.38E-16

1.54E-14

DHCR24

1.15

2.53E-18

6.38E-17

FASN

2.55

9.20E-23

3.11E-21

LDLR

1.85

4.35E-24

1.64E-22

LRP1

3.15

2.57E-44

2.96E-42

LRP10

2.18

1.32E-46

1.68E-44

LRP5

2.15

9.40E-23

3.17E-21

PNPLA6

2.33

2.24E-29

1.16E-27

SCAP

1.97

8.06E-42

8.34E-40

SREBF1

2.75

1.84E-56

3.64E-54

SREBF2

1.68

2.38E-35

1.70E-33

SDHA

1.814

2.329

1.22
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